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Abstract 
The A Disintegrin-like and Metalloproteinase with Thrombospondin-Type 1 
Repeats (ADAMTS) family are a subset of the metzincin superfamily. The 
proteoglycanase sub-family, which comprises ADAMTS1, 4, 5, 8, 9, 15 and 20, 
have the essential role of processing the extracellular matrix (ECM) that has 
important implications during development, tissue maintenance and disease. A 
number of functions for the proteoglycanases have been discovered, including in 
the development of the cardiac valves and secondary palate, and they have also 
been implicated in numerous diseases, such as cancer and arthritis. However, our 
knowledge of the proteoglycanases remains incomplete, considering their broad 
importance and potential as pharmacological targets. This thesis, spanning from 
development to disease, describes the study of the biosynthesis and expression of a 
previously uncharacterised proteoglycanase ADAMTS15, the functional analysis 
of ADAMTS5 in an alternative vertebrate model and the analysis of statins as 
potential new therapeutics for arthritis via their action on ADAMTS4 and 
ADAMTS5.  
ADAMTS15 remains a poorly characterised proteoglycanase with its biosynthesis 
and expression previously unknown. It has, however, been demonstrated to act as 
a tumour suppressor in colorectal and breast cancers. Chapter 3 of this thesis 
describes the propeptide processing of the ADAMTS15 zymogen by the proprotein 
convertase furin. It demonstrates ADAMTS15 expression on the cell surface and 
extracellularly, and a requirement for propeptide excision prior to cleavage of 
versican, as previously described for several proteoglycanases. Broad expression 
of ADAMTS15 was also observed in the developing mouse embryo and adult. This 
 x 
 
research has revealed that ADAMTS15 has the biochemistry of a typical 
versicanase with a novel expression pattern, knowledge that may be applicable to 
understanding its function in cancer.  
ADAMTS5 has been studied in more detail. However, the role of ADAMTS5 
during the gastrulation and somitogenesis stages of early embryogenesis has 
remained uncharacterised due to difficulties in using the mammalian mouse model. 
Chapter 4 of this thesis used the zebrafish as a malleable vertebrate model of 
development to determine the function of ADAMTS5 during these early 
developmental stages. Silencing of ADAMTS5 in the zebrafish led to disrupted 
distribution of the morphogen Shh during gastrulation and somitogenesis, which 
led to further developmental defects, such as perturbed notochord and muscle 
development. Impaired TGF-β signalling during gastrulation was also identified. 
Therefore, ADAMTS5 plays a crucial role in regulating important developmental 
pathways such as Shh and TGF-β signalling in the embryo that has downstream 
implications in muscle formation. These data also suggest that ADAMTS5 has 
important functions independent of its proteoglycanase activity.  
ADAMTS4 and ADAMTS5 cleave aggrecan in cartilage, a process which has been 
implicated in arthritis. Therapeutics that concurrently target these ‘aggrecanases’ 
and the chronic inflammation associated with arthritis are of considerable 
therapeutic interest. Statins, currently prescribed for hypercholesterolemia, 
potentially have both anti-inflammatory and chondroprotective effects in arthritis. 
Chapter 5 of this thesis assessed the potential efficacy of statins in both 
osteoarthritis and rheumatoid arthritis patients in a pilot retrospective study. This 
identified that statins inhibited sulphated glycosaminoglycan release in 
osteoarthritis patients. In contrast, levels of the ARGSVIL aggrecan neoepitope 
 xi 
 
were increased and rheumatoid arthritis patients on statins had no improvements in 
DAS28 clinical scoring or in sulphated glycosaminoglycan release. These findings 
are consistent with conflicting data that surrounds the use of statins in arthritis. 
However, this research may have revealed a potential novel mechanism by which 
statins may inhibit aggrecan degradation that can be further investigated in larger 
prospective studies. 
The research detailed in this thesis has identified novel functional roles for specific 
ADAMTS proteoglycanases. Characterisation of the biochemistry and expression 
of ADAMTS15 will further advance studies aimed at understanding its mechanism 
of action in disease, such as in colorectal and breast cancer. Furthermore, zebrafish 
have been identified as an ideal vertebrate model to study the genetic interactions 
between the ADAMTS proteoglycanases with crucial signalling pathways during 
early development. Finally, the analysis of statins in a clinical setting provides 
precedence for future prospective studies of novel therapeutics that inhibit cartilage 
destruction by the aggrecanases. Collectively, this research provides insight into 
the function, expression and inhibition of the ADAMTS proteoglycanases from 
development to disease, which makes a significant contribution to the field of 
matrix biology.    
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1 Introduction  
1.1 ADAMTS Proteoglycanases and Their Substrates 
 
The A Disintegrin-like and Metalloproteinase Domain with Thrombospondin-1 
motifs (ADAMTS) proteinases belong to the metzincin (zinc-dependent 
metalloproteinase) superfamily; complex secreted enzymes that remodel the 
extracellular matrix (ECM) (1). The ADAMTS family, of which there are 19 
members in mammals (Figure 1.1), display crucial and wide-ranging functions as 
demonstrated by their roles in human disease. For example, ADAMTS13 mutations 
cause thrombocytopenic purpura (TTP), ADAMTS10 mutations cause recessive 
Weill-Marchesani syndrome, ADAMTS2 mutations cause Ehlers-Danlos 
syndrome type VIIC and ADAMTS17 mutations cause Weill-Marchesani-like 
syndrome (2-5). The related ADAMTS-Like (ADAMTSL) proteins (Figure 1.1) 
also play important roles in disease; mutations in ADAMTSL2 cause geleophysic 
dysplasia and a homozygous ADAMTSL4 mutation has been identified in an 
autosomal recessive case of ectopia lentis (6, 7).  
Proteoglycanases represent a conserved subset of ADAMTS proteins that show 
proteolytic activity towards the hyalectan/lectican class of proteoglycans, and 
include ADAMTS1, ADAMTS4 (aggrecanase-1), ADAMTS5/11 (aggrecanase-2), 
ADAMTS8, ADAMTS9, ADAMTS15 and ADAMTS20 (Figure 1.1) (1, 8). The 
proteoglycanases all share a highly conserved N-terminal region containing a signal 
peptide, a propeptide and a catalytic domain (Figure 1.1).  Removal of their 
propeptide occurs either prior to or after secretion into the ECM (1), depending 
upon the proteoglycanase (9, 10). This is mediated by proprotein convertases such 
as furin and PACE-4 (9, 11, 12) extracellularly, in the case of ADAMTS5 (13, 14), 
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on the cell surface, in the case of ADAMTS4 and ADAMTS9 (15, 16), or 
intracellularly, in the case of ADAMTS1 and ADAMTS4 (17-20). This processing 
is typically essential for effective cleavage of their proteoglycan substrates, through 
exposure of the zinc ion contained within the catalytic domain. However, there are 
exceptions. For example, propeptide processing of ADAMTS9 reduces its 
proteolytic activity rather than enhancing it because the propeptide remains tightly 
bound to its catalytic domain after excision (16).  
The ancillary domain of the ADAMTS proteoglycanases is required for substrate 
recognition, as well as correct tissue compartmentalisation (Figure 1.1) (9). Several 
ADAMTS proteinases are modified by proteolysis in their ancillary domains 
including ADAMTS1, ADAMTS4, ADAMTS5 and ADAMTS9, possibly altering 
their substrate recognition and localisation properties that can affect their function 
(9, 10). For example, ADAMTS1 processing in the ancillary domain may be 
relevant in modulating its anti-angiogenic properties (12). Furthermore, 
ADAMTS4 contains multiple glycosaminoglycan (GAG) binding sites located in 
its ancillary domain that may regulate its function (21). In different contexts, 
proteolysis in the ancillary domain may inactivate or reduce the activity of the 
proteoglycanases towards specific substrates. Proteolysis in the ancillary domain 
may also be autocatalytic, although other proteases may also be involved. For 
example, glycosylphosphatidyl inositol-anchored membrane type-4 matrix 
metalloproteinase (MT4-MMP) cleaves ADAMTS4 in its C-terminal domain, 
enabling cell-surface activation (22). In addition, the fragments released may have 
their own biological functions independent of the catalytic functions of the 
proteinase, in a manner similar to ADAMTSL proteins which contain only an 
ancillary domain (Figure 1.1) and have functions such as regulating the 
 3 
 
bioavailability of transforming growth factor-beta (TGF-β) in human fibroblasts 
(6), skeletal myogenesis during mouse embryogenesis (23) and postsynaptic 
domain specification in the nematode, Caenorhabditis elegans (C. elegans) (24). 
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Figure 1.1. Structure of the ADAMTS and ADAMTS-Like proteins  
The ADAMTS proteinases contain a protease domain responsible for their enzymatic activity. The 
pro-domain of the proteoglycanases (ADAMTS1, 4, 5, 8, 9, 15 and 20) requires cleavage from the 
catalytic domain to expose the zinc ion to its substrate proteoglycans such as versican and aggrecan. 
The ADAMTS-Like (ADAMTSL) proteins contain only an ancillary domain (1, 9).                         
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The ancillary domain of ADAMTS enzymes contains a disintegrin-like domain, 
cysteine-rich domain, spacer region, as well as a variable number of 
thrombospondin (TS) type-1 motifs with additional domains located on some of the 
ADAMTS family members (Figure 1.1). The disintegrin-like domain is situated 
directly adjacent to the active site, confirmed by analysing crystal structures of 
ADAMTS1, ADAMTS4 and ADAMTS5, implying that it may have a regulatory 
function, possibly by acting as a secondary substrate-binding surface (25-27). The 
central TS-1 repeat is highly conserved, as is the cysteine-rich domain, containing 
10 well-conserved cysteine residues (Figure 1.1) (27). The spacer regions in the 
proteoglycanases have variable lengths and represent the least conserved domain 
(Figure 1.1) (27). Proteoglycanases have from zero to fourteen TS-1 repeats 
following the spacer domain at the C-terminus, in combination with other regions 
specific to particular proteoglycanases, such as the GON-1 module in ADAMTS9 
and ADAMTS20 (Figure 1.1) (9, 28). The C-terminal TS-1 repeats have more 
variable sequences compared to the central TS-1 repeat; however, their function 
also appears to be matrix binding (9, 27).  
All proteoglycanases are predicted to contain various post-translational 
modifications including N-glycosylation, O-fucosylation and C-mannosylation 
(10). Thus far, N-glycosylation sites have been confirmed in ADAMTS1, 
ADAMTS5 and ADAMTS9 (10, 16, 17). ADAMTS5 is the only proteoglycanase 
where O-fucosylation and C-mannosylation sites have been confirmed (29). These 
modifications may be essential for secretion from the cell. Mutations of the putative 
ADAMTS5 N-glycosylation sites at N728, N802 and N807 to glutamines by site-
directed mutagenesis increased the electrophoretic mobility of ADAMTS5, while 
its secretion into the extracellular environment was reduced (29). Further, N-
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glycosylated ADAMTS5 was efficiently secreted from fucose deficient LEC-1 
cells, suggesting N-glycosylation has a dominant role over O-fucosylation in 
ADAMTS5 secretion (McCulloch and Apte, unpublished and (10)). In addition, 
mutation of the N-glycosylation sites on the ADAMTS9 propeptide caused a 
reduction of ADAMTS9 ProCat secretion (16). Unlike ADAMTS9, ADAMTS5 
does not contain its N-glycosylation sites on its propeptide. However, its secretion 
into the extracellular matrix upon mutation of its N-glycosylation sites was reduced 
despite this (10), suggesting a clear difference between the regulation of 
ADAMTS5 and ADAMTS9. ADAMTS4 has one predicted but unconfirmed N-
glycosylation site (10). O-fucosylation and C-mannosylation modifications have as 
yet unknown roles, although the secretion of ADAMTSL1 (Punctin) was found to 
be inhibited from the cell upon removal of O-fucosylation and C-mannosylation 
sites (29, 30).     
The ADAMTS proteoglycanases show preferential proteolytic activity towards the 
hyalectan family of chondroitin sulphate proteoglycans (CSPGs), which comprise 
aggrecan, versican, neurocan and brevican (Figure 1.2) (31). The hyalectan group 
of CSPGs share an N-terminal G1 domain with a signal peptide, a chondroitin 
sulphate (CS) or glycosaminoglycan (GAG) region, and a C-terminal G3 domain 
(Figure 1.2) (32). The G1 domain contains a hyaluronan (non-sulphated, high 
molecular weight GAG) binding region, allowing it to form aggregates, which 
contribute to a rigid, yet flexible, ECM (Figure 1.2) (31, 33). The C-terminal region 
of the CSPGs interacts with lectins, which bind various carbohydrates (33). The 
cleavage of hyalectans by proteoglycanases occurs at Glu-Xaa motifs located in the 
core protein (10). Versican and aggrecan are cleaved to produce the cleavage 
fragments G1-DPEAAE (Versikine) (13, 34, 35) and G1-EGE, respectively (36). 
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Versican consists of different isoforms encoded by 4 splice variants (V0, V1, V2 
and V3). V0 and V1 are the most widely distributed, being present in brain, heart, 
lung, skin and skeletal muscle, whereas V2 and V3 are restricted to the CNS (37-
40). Aggrecan is predominately found in brain and cartilage, but also in tendon, 
eye, spinal cord as well as heart valves in some vertebrates (41-43). On the other 
hand, neurocan and brevican are predominately restricted to the CNS (44-51). 
ADAMTS1, ADAMTS4 and ADAMTS5 show proteolytic activity towards all four 
hyalectan CSPGs (Figure 1.2) (13, 52-59). ADAMTS8 and ADAMTS15 are known 
to cleave aggrecan (60-62), ADAMTS9 shows proteolytic activity towards 
aggrecan and versican (28) and ADAMTS20 cleaves versican (63).  
1.1.1 ADAMTS Proteoglycanases in Development 
Independently, or in cooperation, the ADAMTS proteoglycanases have 
pronounced roles during development largely attributed to their proteolytic activity 
towards versican. Indeed, versican deficient (hdf-/-) mice die during gastrulation at 
E9.5 from a heart defect, demonstrating the importance of versican during 
embryogenesis (64). Adamts9+/-; Adamts20-/- mice present with a fully penetrant 
secondary cleft palate (65). Additionally, Adamts9+/-; Adamts20-/- and Adamts20-/- 
mice present with a defect in melanoblast colonisation and survival, with a 
reduction of versican cleavage at the site of depigmentation (63). Adamts9-/- mice 
show embryonic lethality and die at E7.5, prior to cardiovascular development (65). 
However, Adamts9+/- mice present with cardiac anomalies such as chondrogenic 
nodules and myxomatous heart valves, associated with versican accumulation (63, 
66).  
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Adamts1-/- mice displayed impaired ovarian folliculogenesis and infertility linked 
to decreased versican cleavage (67, 68). These mice also presented with kidney 
dysgenesis and interstitial fibrosis evident at birth, leading to death of almost half 
of Adamts1-/- pups neonatally, although the surviving embryos largely escape 
adverse effects of the kidney deformity (69, 70). However, this phenotype was 
exacerbated in Adamts1-/-; Adamts4-/- combinatorial knockout mice with most of 
the mice dying within 72 h after birth due to prominent renal medulla thinning, 
despite Adamts4-/- mice not presenting with a phenotype (71, 72). Therefore, both 
Adamts1 and Adamts4 have essential roles in kidney development. Adamts4-/-; 
Adamts5-/- combinatorial knockout mice have been generated, but perinatal lethality 
was not observed. However, Adamts5 was expressed in the developing kidney; 
therefore ADAMTS5 may also have roles independent of ADAMTS1 and 
ADAMTS4 during kidney development (34, 73, 74).  
Adamts5 was highly expressed during mouse embryogenesis, especially after E11.5 
in the central and peripheral nervous systems, as well as after E13.5 in the 
musculoskeletal system, specifically in the emerging forelimb, hindlimb, tail, facial 
and paraspinal muscles, as well as in the interdigital mesenchyme and 
perichondrium surrounding the digit skeleton in forelimbs and hindlimbs (74). 
Expression of Adamts5 has been specifically detected in skeletal myoblasts, which 
differentiate to give rise to muscle cells (74). This is in line with a role for 
ADAMTS5 and ADAMTS15 cooperatively promoting myoblast fusion through 
versican processing in vitro (75).  Adult mice show expression of Adamts5 in cell 
types such as the mesangial cells of the kidney glomeruli, cardiac and hepatic 
endothelial cells, as well as glial and Schwann cells of the central and peripheral 
nervous systems, respectively (74). With such a wide range of expression, it is 
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expected that ADAMTS5 has a widespread role during development. Adamts5, 
Adamts9 and Adamts20 are co-expressed (with versican) in the interdigital 
mesenchyme during web regression and all cooperate to stimulate interdigital 
apoptosis, forming the penatameric digits, again associated with versican cleavage 
(34, 76). Additionally, Adamts5 deficient mice present with myxomatous heart 
valves due to decreased versican cleavage fragments and increased full-length 
versican (77). Currently, there are no published Adamts8 or Adamts15 knockout 
mice to ascertain the roles of these family members in development.  
1.1.2 ADAMTS Proteoglycanases in Disease 
The ADAMTS proteoglycanases contribute to a variety of disease states. For 
example, ADAMTS5 (aggrecanase-2) is the most well-known ‘aggrecanase’ that 
cleaves and destroys aggrecan in cartilage in arthritic conditions, with mice bearing 
inactive alleles of this gene protected from experimentally induced arthritis (78, 
79). Aggrecanase (ADAMTS4 and ADAMTS5) activity is evident in synovial fluid 
from arthritic patients, however, which ADAMTS is the dominant aggrecanase or 
whether more than one cooperatively degrade cartilage in human arthritis remains 
unknown (80, 81).   
Dysregulated expression of multiple ADAMTS proteoglycanases has been detected 
in head and neck squamous cell carcinomas (HNSCCs), suggesting a role for these 
proteinases in HNSCC progression (82). However, generally studies regarding 
ADAMTS proteinases in human cancers have shown differential specificity in their 
roles, with respect to different cancers, or at different cancer stages (83). Recent 
research indicated ADAMTS1 was essential for mammary tumour growth and 
metastasis (84), with ADAMTS1 overexpressed in human primary breast cancers 
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with bone metastasis (85). A catalytically-inactive Adamts1 mutant inhibited 
metastasis in mouse mammary and lung carcinoma cells suggesting its 
prometastatic function can be attributed to its catalytic activity (86). In contrast, 
ADAMTS1 was decreased in prostate cancer suggesting it may have an anti-
angiogenic and anti-metastatic role in hormone-refractory prostate cancer (87).  
ADAMTS8 and 15 expression predicts survival in human breast carcinoma 
whereby high ADAMTS8 and low ADAMTS15 expression was indicative of a 
particularly poor prognosis, with a 3-fold higher chance of cancer recurrence and a 
5-fold chance of death (88). ADAMTS15 was found to be genetically inactivated in 
colorectal cancer, further demonstrating its tumour suppressor properties (89). 
Downregulation of ADAMTS9 in oesophageal and nasopharyngeal carcinoma also 
indicated a potential role for this proteoglycanase as a tumour suppressor gene (90, 
91). Recently, ADAMTS5 was found to have anti-tumourigenic and anti-
angiogenic properties independent of its proteoglycanase activity (92). In addition, 
gliomas (invasive tumours of the CNS), displayed an upregulation of ADAMTS5, 
but not ADAMTS1 or ADAMTS4 (59). Moreover, brevican cleavage, most likely 
facilitated by ADAMTS proteoglycanases (ADAMTS5 the most likely candidate), 
was shown to promote glioma invasion (93). 
In other pathologies, increased ADAMTS5 expression has been associated with 
herniated intervertebral disc degeneration and decreased proteoglycan 
accumulation (94). ADAMTS4 and ADAMTS8 have been implicated as 
inflammation-regulated enzymes, being expressed in macrophage-rich areas of 
human atherosclerotic plaques (95). ADAMTS1 was predicted to stimulate 
atherogenesis by cleaving ECM proteins like versican and promoting vascular 
smooth muscle cell migration (96). Recently, ADAMTS5 has been found to 
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regulate vascular proteoglycan catabolism and alter lipoprotein retention in 
atherosclerosis (97). ADAMTS5 and ADAMTS8 were also found in macrophages 
associated with abdominal aortic aneurisms, indicating a potential role in 
macrophage infiltration (98). ADAMTS5 may also have a unique role in tissue 
repair signalling, since deletion of Adamts5 inhibited dermal repair in mice, 
proposed to be through CD44-mediated aggrecan accumulation and subsequent 
modulation of TGF-β1 signalling (99).  
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Figure 1.2. Structure of the proteoglycans 
The proteoglycans all contain a G1 domain, hyaluronan associated binding region (HABR), link 
proteins, core protein, chondroitin sulphate glycosaminoglycans (GAG) and G3 domain, containing 
epidermal growth factor (EGF)-like domain, lectin-like domain and complement regulatory protein 
(CRP)-like domain. The proteoglycans are all associated with hyaluronan, which provides a rigid 
yet flexible extracellular matrix. Hyaluronan is bound to the cell-surface receptor CD44. Aggrecan 
is predominately located in the cartilage and versican is abundant throughout most of the body, 
whereas neurocan and brevican are located in the CNS (41). Localisation of glycosaminoglycan 
chains are a guide only.   
 
 
 
 
 
 
 
 
 
 
Link-protein 
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1.1.3 The Evolution of ADAMTS Proteoglycanases  
C. elegans was shown to possess a single ADAMTS orthologue called GON-1, 
responsible for gonadal morphogenesis. This showed greatest similarity to the 
mammalian ADAMTS9 and ADAMTS20 (28, 100) that contain almost identical 
structures with 15 thrombospondin type-1 repeats and the unique GON-1 region, 
suggesting they arose through gene duplication (28). It has also been shown that 
GON-1 and ADAMTS9 share the ability to promote protein transport from the 
endoplasmic reticulum (ER) to the Golgi apparatus (101). Additionally, 
ADAMTS9 (and ADAMTS4) was able to substitute for GON-1 in transgenic 
nematodes (28, 102). Collectively, this suggests conservation of proteoglycanases 
throughout evolution, arising from a common ancestor related to GON-1. 
The ascidian Ciona intestinalis, a urochordate which is the closest extant relative 
of vertebrates, was found to possess only two ADAMTS proteoglycanase genes, 
adamtsd (related to ADAMTS9 and ADAMTS20) and adamtsf (related to 
ADAMTS1, ADAMTS4, ADAMTS5, ADAMTS8 and ADAMTS15) (103). This 
suggests that during vertebrate evolution, the ADAMTS proteoglycanase family 
has expanded, most likely including the two whole genome duplication events 
during this time (103).  
In zebrafish (Danio rerio), the ADAMTS proteoglycanase orthologues have been 
evolutionarily conserved, with homologues for each of ADAMTS1, 5, 8, 9, 15 and 
20 identified (104). However, no zebrafish orthologues of ADAMTS4 have been 
found, suggesting their functions are not essential in this organism (41, 103, 104). 
In contrast to previous reports, it is now known that zebrafish have two orthologues 
for both ADAMTS8 (adamts8a and adamts8b) and ADAMTS15 (adamts15a and 
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adamts15b), which are likely a result of an additional whole genome duplication 
event in teleost fish (41, 103, 104). These additional orthologues may have taken 
on additional functions to compensate for the loss of ADAMTS4 (104). 
Despite this, the ADAMTS proteoglycanase catalytic domains remain highly 
conserved between vertebrates (41, 104). This conservation suggests both that the 
ADAMTS genes are likely to be of critical importance, and that further analysis of 
their functions in one vertebrate will be informative to other vertebrate species.  
1.1.4 Evolution of the Hyalectan/Lecticans  
In Ciona, no orthologues have been found for many ECM components including 
the chondroitin sulphate proteoglycans. (105). It is therefore most likely these genes 
evolved de novo during early vertebrate evolution to attain their specialised roles 
(105). Zebrafish possess two aggrecan genes, acana and acanb, on chromosomes 
7 and 25 (41). In zebrafish, aggrecan (acana) was expressed in elements of the 
craniofacial cartilage bones, such as the pharyngeal arch, neurocranium and the 
pectoral fin (106), and was also present in the peri-notochordal sheath indicating it 
may be involved in notochord development (part of the presumptive axial skeleton 
involved in specifying ventral fates in the CNS and circulatory system) (107, 108). 
In chick embryos, aggrecan was present in later stages of development in 
mesenchymal cells, epicardium, the sino-atrial junction and the basement 
membrane of the notochord (109-111). It has been further demonstrated that 
aggrecan was involved in chondrogenesis and gangliogenesis in the chick brain, 
consistent with findings in mice (112-116).  
Zebrafish versican, encoded by vcana, comprises only a small portion of the 
equivalent mammalian versican, containing just the G3 globular domain (41). 
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However, this domain controls important pathological processes, such as 
melanoma tumour growth and metastasis (117). Wide expression of vcana in 
zebrafish was demonstrated, including in adaxial mesoderm (slow muscle 
precursor cells), lateral plate mesoderm lining and circulatory precursor cells, and 
more laterally in paraxial mesoderm (fast muscle precursor cells) (106, 118). 
Further, in zebrafish, it was also found in the heart, lens and otic vesicle (auditory 
vesicle), an expression pattern consistent with expression of versican in other 
vertebrates such as chick and mouse (64, 106, 109, 112). Zebrafish dermacan 
(encoded by vcanb) showed homology across all regions of human full-length 
versican (V0), including the N-terminal region that is known to be cleaved by 
ADAMTS proteoglycanases (106). The cleavage site targeted by ADAMTS 
proteoglycanases DPEAAE↓A was also conserved in zebrafish dermacan, 
represented by the sequence VAEQE↓A (41), although it remains to be determined 
whether dermacan is remodelled by ADAMTS proteoglycanases during zebrafish 
development. However, dermacan has been shown to be expressed in zebrafish 
dermal bone development in structures such as the sclerotome (which later 
differentiates into the skull, vertebrae and ribs), tail fin bud, otic vesicle, and 
craniofacial bones, such as the opercle (gill cover) and dentary (mandible) and near 
the midbrain (106). In addition, dermacan knockdown zebrafish showed decreased 
ossification in dermal bones, suggesting an important role in bone development 
(106).  
In chick embryos, versican staining was prominent in the heart early in 
development, whereby its expression was evident throughout the myocardium, the 
basement membrane between the myocardium and endocardium and the sino-atrial 
junction (109). Versican was also expressed in the neural tube, notochord and 
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sclerotome of the developing chick (112). Additionally, versican V0 and V1 has 
been shown to guide migratory neural crest cells, and versican has a separate role 
during synovial joint morphogenesis in the chick embryo (119, 120), data 
consistent with the findings obtained from the zebrafish and mouse (64, 106). 
Interestingly, conditional versican knockout mice (Prx1-Cre/Vcanflox/flox) displayed 
distorted digits, hypertrophic chondrocytic nodules in their cartilage, joint tilting 
and delayed chondrocytic differentiation in digits, suggesting versican facilitates 
joint morphogenesis and chondrogenesis (121). Further, versican immunostaining 
was prominent in mouse embryonic craniofacial structures, such as the tooth 
mesenchyme, mandible and maxilla; at E13.5-E14, versican was readily detected 
in the palatal mesenchyme, the strongest being towards the nasal cavity (122).  
Brevican and neurocan were found to be predominately CNS-restricted CSPGs and 
synthesised by glial cells and neurons (123). Brevican, first isolated from bovine 
brain, was widely distributed in the rat and bovine brain and was localised 
extracellularly (124, 125). In Xenopus, brevican was expressed in the brain and 
notochord during early embryogenesis (126). Neurocan has been isolated from the 
adult and early postnatal rat brain (127) and has been shown to moderate neuronal 
adhesion and growth during development by binding to neural cell adhesion 
molecules in rat cells (44). However, neurocan was also involved in modulating rat 
retinal vasculature and was found in the rat optic nerve (128, 129). In addition, 
neurocan has also been found in the embryonic avian heart and vasculature, 
although later it becomes restricted to the CNS along with brevican, at least in birds 
(123, 130). Neurocan upregulation may also occur in disease such as rat retinal 
ischemia, chronic CNS glial scarring in rats and has been linked to schizophrenia 
and bipolar disorders in humans (131-134). Brevican predominately promoted glial 
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cell motility during development, and upregulation has also been associated with 
glioma invasion (54, 57, 59, 123, 135). These data suggest the hyalectan 
proteoglycan expression patterns and functions are highly conserved across 
vertebrate species.       
1.1.5 The Zebrafish as a Model of Vertebrate Embryogenesis 
The zebrafish has emerged as an important model used to elucidate the roles of 
mammalian gene orthologues throughout vertebrate embryogenesis (136). 
Zebrafish development occurs quickly, such that within 72 hours the major aspects 
of zebrafish morphogenesis are essentially completed (137). Importantly, zebrafish 
embryos are optically transparent, with internal structures easily visualised using 
an inverted stereomicroscope (138). As their development occurs ex utero, this 
enables easy analysis of embryos through techniques such as whole-mount in situ 
hybridisation (WISH) or immunohistochemistry for detection of internal structures. 
Furthermore,  the embryos are accessible for the application of gene overexpression 
or gene knockdown techniques such as microinjection of mRNA or morpholino 
antisense oligonucleotides (MOs), or complete genome targeting techniques such 
as Zinc-Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases 
(TALENs) and Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR) and CRISPR associated systems (Cas) (139-143). A practical advantage 
of gene knockdown using morpholinos in zebrafish is that penetrance is variable; 
meaning a range of phenotypes are observed in individual embryos depending on 
the dosage (138). The subsequent phenotypes may be due to a complete knockdown 
or partial knockdown in the one experiment, therefore, a variety of functions can 
be elucidated (138). This property may assist with analysing the function of 
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mammalian orthologues whose complete ablation causes embryonic lethality in the 
mouse, such as ADAMTS9 (65).  
1.2 Arthritis and the ADAMTS Aggrecanases 
This section of Chapter 1 has been published as the following review article: 
Current and Emerging Therapeutic Strategies for Preventing Inflammation 
and Aggrecanase-Mediated Cartilage Destruction in Arthritis by Carolyn M 
Dancevic and Daniel R McCulloch. Arthritis Research and Therapy 2014; 
16:429.  
Arthritis is a debilitating degenerative disease of articular joints predominately 
characterised by articular cartilage degradation, alterations to subchondral bone 
mass and localised inflammation. The substantial impact on health care budgets in 
Western nations is evidenced by an estimated health care burden of 50 million 
adults (22%) in the USA with arthritis being a leading cause of disability worldwide 
(144, 145). Inflammatory cytokines, such as interleukin-1 (IL-1), interleukin-6 (IL-
6) and tumour necrosis factor-α (TNF-α), are expressed locally in the articular joint 
cause inflammation, stimulating the production of cartilage-degrading zinc-
dependent Matrix Metalloproteinases (MMPs) such as MMP1, MMP2, MMP3, 
MMP9 and MMP13, as well as the ADAMTS proteinases, predominately 
ADAMTS4 and ADAMTS5 or the ‘aggrecanases’ (146, 147). 
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1.2.1 Roles of Matrix Metalloproteinases and ADAMTS in Cartilage 
Formation 
An equilibrium exists between metalloproteinases and their inhibitors to maintain 
a balance between anabolism and catabolism in articular cartilage. In arthritis, 
disequilibrium favours the catabolism of cartilage whereby protease activity 
outweighs their inhibition by Tissue Inhibitors of Metalloproteinases (TIMPs). 
Although MMP and ADAMTS enzymes are responsible for the degradation of 
cartilage in arthritic disease, their roles in cartilage development and remodeling 
are crucial for joint formation and homeostasis.  
MMP1 and MMP2 have been shown to be localised in synovium and joint articular 
surfaces in human foetal limbs at 7-14 weeks gestation, suggesting roles for these 
proteases in the development and remodelling of synovial tissue and articular 
cartilage (148). Mmp9-/- mice exhibited delayed apoptosis, ossification and 
vascularisation of hypertrophic chondrocytes, resulting in progressive growth plate 
lengthening, revealing a requirement for MMP9 in angiogenesis and ossification of 
the developing growth plate (149). Furthermore, Mmp13-/- mice exhibited defects 
in growth plate cartilage, with expanded hypertrophic chondrocyte zones and 
increased trabecular bone as well as increased interstitial collagen accumulation. 
Combinatorial Mmp9-/; Mmp13-/- mice displayed an exacerbated phenotype, 
suggesting synergy between these two proteases in cartilage and bone formation 
(150, 151). Importantly, mutations in MMP9 and MMP13 in humans cause 
disorders in bone and cartilage growth leading to developmental phenotypes such 
as metaphyseal dysplasia and spondyloepimetaphyseal dysplasia, Missouri type 
(152, 153), which are disorders characterised by abnormal growth and development 
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of long bones and vertebrae. Mmp14 (MT1-MMP) deficient mice display severe 
skeletal abnormalities including impaired vascularisation of epiphyseal cartilage 
leading to delayed ossification and hypertrophic zone lengthening, revealing a role 
for Mmp14 in angiogenesis and bone growth (154). Significantly, human mutations 
in MT1-MMP cause Winchester syndrome, associated with progressive osteolysis, 
osteoporosis and joint erosions (155).  
It has yet to be established whether ADAMTS4 or ADAMTS5 have a role in the 
development and growth of cartilage and bone, although their expression is 
upregulated in arthritic disease. The other ‘aggrecanases’ include ADAMTS1, 
ADAMTS9 and ADAMTS15, which may also have roles during cartilage and bone 
development. Although Adamts1 mRNA was expressed in growth plate and 
articular cartilage during normal mouse development and was upregulated in 
hypertrophic differentiation of growth plate chondrocytes, it does not play a 
significant role in cartilage and bone development and growth (156) or in arthritis. 
Adamts9 mRNA was also expressed from 13.5 days post coitus (dpc) during mouse 
embryogenesis in the perichondrium, the proliferative zone in the growth plate and 
bone (157) and  but roles for ADAMTS9 have not yet been elucidated in cartilage 
and bone development nor in arthritic disease. However, aggrecan degradation 
facilitated by MMP and ADAMTS enzymes is a process that occurs within both 
normal and arthritic cartilage signifying a role for these proteases in normal 
turnover as well as in arthritis (158), whilst structural changes in aggrecan also 
occur during healthy ageing (159).  
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1.2.2 Enzymatic Processing of Joint Cartilage 
MMP activity was upregulated in arthritic cartilage and synovial fluid (160, 161), 
which correlated with type II collagen cleavage (162). The collagenases (MMP1, 
MMP8 and MMP13) were shown to preferentially degrade type II collagen 
(collagen II) at Gly775↓776Leu causing loss of its trimeric structure, exposing it to 
further degradation (163). MMP2 and MMP9 (the gelatinases), and MMP3 
(stromelysin), which degrade non-collagen matrix components of the joint, also 
promoted further degradation of denatured collagen II following cleavage by 
collagenases (164). MMPs were also able to degrade aggrecan. MMP3, first 
isolated from human articular cartilage, cleaves the Asn341↓342Phe bond in the 
interglobular domain (IGD) of aggrecan (165, 166).  However, it was recently 
shown that MMP-generated aggrecan fragments were predominately involved in 
normal aggrecan turnover with their preferred cleavage site located C-terminal to 
the IGD, and may have a lesser role in aggrecan degradation in knee injuries and 
OA in human cartilage (167).  
In contrast to collagen II degradation by MMPs, aggrecan degradation by 
aggrecanases was an early and reversible event (168). Furthermore, since presence 
of aggrecan prevents collagen II degradation, and may therefore impart overall 
cartilage protection (169, 170), inhibiting aggrecan degradation via the ADAMTS 
aggrecanases may be a potential therapeutic strategy to prevent further collagen II 
degradation. ADAMTS4 and ADAMTS5/ADAMTS11 (56, 58, 171) cleave 
aggrecan in its C-terminal chondroitin sulphate (CS) rich domains (Figure 1.3) at 
the following sites: SELE1545↓1546GRGT, KEEE1714↓1715GLGS, 
TAQE1819↓1820AGEG, ISQE1919↓1920LGQR. However, the most detrimental 
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cleavage is thought to occur within its IGD at TEGE373↓374ARGS (Glu373↓374Ala 
bond), generating G1-NITEGE fragments that releases the entire CS-rich region 
into the synovial fluid compromising joint function (reviewed in Fosang et al. (172) 
- Figure 1.3).  
1.2.3 Aggrecanases and Their Contribution to Arthritis 
In 2005, two independent landmark studies demonstrated catalytic-inactivation of 
Adamts5 protected mice from experimentally-induced OA and RA (78, 79) but 
Adamts4 deficient mice or those expressing catalytically-inactivated Adamts4 did 
not show this same protection. However, whether ADAMTS4 or ADAMTS5 is the 
most predominant enzyme responsible for the cleavage of aggrecan in arthritis in 
humans remains controversial. Whilst ADAMTS5 has been shown to cleave 
aggrecan extensively in human arthritic synovium and was abundant and widely 
distributed in human OA cartilage (173), other data has indicated that both 
ADAMTS4 and ADAMTS5 cooperated to mediate aggrecan degradation in human 
articular cartilage explants (174) and an ADAMTS4 splice variant (ADAMTS4_v1) 
was found to cleave aggrecan in human OA synovium (175).  
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Figure 1.3. The cleavage of aggrecan and the impact of therapies that slow radiographic 
progression of arthritis 
Full-length aggrecan resides in the pericellular matrix attached to hyaluronan via link protein. 
Hyaluronan is bound to its cell surface receptor CD44 on articular chondrocytes. ADAMTS4 and 
ADAMTS5 cleavage (scissors) within the interglobular domain (IGD) of aggrecan is the most 
detrimental to cartilage function in arthritis as it releases the entire chondroitin sulphate (CS)-
modified C-terminus into the synovium. Inhibitors of cytokine activity or ADAMTS5 may prevent 
cartilage loss directly. DMARD, disease-modifying anti-rheumatic drug; G, immunoglobulin-like 
domain; IL, interleukin; KS, keratan sulphate; NSAID, non-steroidal anti-inflammatory drug; TNF-
α, tumour necrosis factor-alpha. Localisation of glycosaminoglycan chains are a guide only.  
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Since arthritis is a disease of the entire joint, ADAMTS4 and ADAMTS5 may have 
variable activity depending on the site and progression of the disease, and also 
which cytokines are present, since this can affect their expression and activation 
profile. Induction of Adamts5 by IL-1α and TNF-α was found to predominately 
occur in synovium and the patellar, but not femoral head or tibial joint cartilage in 
ex vivo mouse joints, indicating ADAMTS5 may not be the predominant 
aggrecanase in articular cartilage mediating arthritis (176). Furthermore, 
expression of ADAMTS4 in bovine menisci was preferentially upregulated by IL-
1α in inner meniscal zones whereas the gene expression of ADAMTS5 was 
preferentially upregulated by TNF-α in outer meniscal zones (177). In human 
osteoarthritic synovium, upregulation of ADAMTS4 was dependent on both IL-1 
and TNF-α unlike ADAMTS5, again suggesting that ADAMTS5 may be more 
active in joint structures other than articular cartilage (178). The differential roles 
of the aggrecanases adds further complexity to potential treatments discussed 
below. However, evidence of their cooperative roles in cartilage degradation and 
common activation by inflammatory cytokines suggest both ADAMTS4 and 
ADAMTS5 represent important therapeutic targets in arthritis.  
1.2.4 Current Arthritis Treatments 
Current strategies for arthritis treatment have favourable outcomes in a subset of 
patients. However, many treatment regimens are inadequate due to poor and often 
patient-specific efficacy issues. They also focus on decreasing pain and 
inflammation associated with the disease but often fail to effectively inhibit 
cartilage destruction, and therefore, disease progression. Further, because many 
treatments lose efficacy over time, the increasing doses often serve to enhance their 
 25 
 
toxicity and other side effects. Current efficacious treatments for RA include 
Disease-Modifying Anti-Rheumatic Drugs (DMARDs) or biological agents such 
as antibodies, with corticosteroid intra-articular joint injections and Non-Steroidal 
Anti-Inflammatory Drugs (NSAIDs) also used for both RA and OA.  
1.2.4.1 Disease-Modifying Anti-Rheumatic Drugs (DMARDs) 
DMARDs are essentially immunosuppressants that include methotrexate, 
sulfasalazine, hydroxychloroquine and leflunomide. Methotrexate is the “gold- 
standard” treatment and now a first-line therapy for RA patients early in the course 
of their disease, with its systemic anti-inflammatory effects (Figure 1.4) mediated 
through inhibiting purine and pyrimidine metabolism. Methotrexate suppresses 
proliferation of synovial fibroblasts, a source of aggrecanase production, and also 
modulates cytokine production (179). Taken together, methotrexate has the 
potential to slow cartilage destruction through the inhibition of ADAMTS4 and 
ADAMTS5 activity (Figure 1.3), although this possibility is yet to be investigated. 
Side effects of methotrexate include abdominal discomfort, alopecia, oral 
ulcerations and cytopenia, which limit its use to low doses thereby compromising 
its efficacy. Despite the improvements this treatment has offered, RA often persists 
after methotrexate regimens and the multifactorial nature of RA means that some 
patients have a poor response to treatment regardless of the dose rate and time of 
administration. Therefore, other DMARDs (such as anti-malarial agents like 
chloroquine) or biological agents (predominantly antibodies - discussed below) are 
often administered in combination with methotrexate where better disease 
outcomes are evident.  
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Figure 1.4. The structure of the articular joint and the mode of action of targeted arthritis 
therapeutics  
Multifaceted components such as ligaments, menisci, and articular surfaces of the articular joint 
confer upon the joint compression-resistance and load-bearing properties. Arthritis may ensue if one 
or more components are compromised. Chondrocytes (dark blue) and synoviocytes (light blue) are 
a source of cytokine production and aggrecanase activity and inflammatory cytokines are found in 
synovial fluid of arthritic joints. Emerging therapeutics such as statins may suppress inflammatory 
cytokine activity in synovial fluid, thereby potentially inhibiting cartilage degradation mediated by 
ADAMTS4 and ADAMTS5. Disease-modifying anti-rheumatic drugs (DMARDs), biological 
agents, corticosteroids, and non-steroidal anti-inflammatory drugs (NSAIDs) may also prevent 
cartilage destruction indirectly by reducing inflammation. Structure of the joint is a guide only and 
not a precise anatomical figure. 
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1.2.4.2 Biological Agents 
Biological agents used to treat arthritis comprise antibodies against inflammatory 
cytokines or their receptors to suppress their activity, which are predominantly used 
in RA. They are typically the second line of defence either after, or in combination 
with, DMARDs. TNF-α inhibitor therapy precedes the discovery of the role of 
ADAMTS4 and ADAMTS5 in cartilage destruction. However, it is now apparent 
that inhibiting TNF-α may lead to a reduction in aggrecanase activity (Figure 1.3). 
Indeed, clinical trials demonstrated that TNF-α inhibitor administration in 
combination with methotrexate resulted in improvements in the symptoms of RA 
including slowed radiographic disease progression in the majority of active RA 
patients (180-182), an effect that could be attributable to reduced ADAMTS4 and 
ADAMTS5 aggrecanase activity. These TNF-α inhibitors include etanercept, a 
human soluble and dimeric TNF type II receptor linked to an IgG1-Fc moiety that 
binds to, and thereby inactivates, TNF-α (182) and golimumab, a humanised anti-
TNF-α monoclonal antibody that has a high selectivity for human TNF-α, also 
effectively neutralising its activity (181). Other examples of efficacious TNF-α 
inhibitors include the human IgG1 monoclonal antibody adalimumab, that binds 
specifically to TNF-α preventing bioavailability to its p55 and p75 receptors (183), 
and infliximab, which is a chimeric (human-mouse) monoclonal antibody against 
human TNF-α, which has produced symptomatic relief and elicited improvement 
in the quality of life in RA patients (184). However, despite their high efficacy, 
approximately 30% of patients with RA have an unsatisfactory response to TNF-α 
inhibitors (185), with side effects including nausea, upper respiratory tract 
infections, dyspepsia and headaches.   
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For patients unresponsive to TNF-α inhibitors, other biological agents have been 
trialled with some success. These include rituximab (B cell inhibitor), abatacept (T 
cell inhibitor), tocilizumab (IL-6 inhibitor) and anakinra (IL-1 inhibitor). Treatment 
with tocilizumab, a human monoclonal anti-IL-6 receptor (anti-IL-6R) antibody 
that competitively inhibits the binding of IL-6 to its receptor (180, 185), has 
demonstrated a significant reduction in symptoms of RA compared to DMARDs 
alone or in combination with methotrexate or other DMARDs (180). Tocilizumab 
and anakinra therapy are of particular interest to aggrecanase biology given 
ADAMTS4 and ADAMTS5 activities can be regulated by IL-6 and IL-1 (147, 176, 
186) (Figure 1.3).  
Abatacept, on the other hand, has been shown to prevent T-cells recognising 
antigen presenting cells, as it comprises a fused Fc domain of IgG with human T-
lymphocyte antigen 4 (187, 188). Abatacept has proven to be as effective as other 
biological agents in patients that failed to respond to other DMARDs (188). 
Rituximab, a chimeric monoclonal antibody that leads to peripheral B-cell 
depletion by blocking the cell surface antigen CD20, demonstrated significant 
improvement in a cohort of RA patients compared to placebo in a phase III study 
(189). In combination with methotrexate, most disease scores were significantly 
improved upon rituximab treatment, although patients did suffer mild to moderate 
side effects including low rates of infection (189).  
As discussed above, IL-1, IL-6 and TNF-α can upregulate ADAMTS4 and 
ADAMTS5 levels and activity and thus indirectly stimulate cartilage destruction. 
Therefore, any biological agent that targets systemic or local mediators of 
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inflammation has the potential to inhibit cartilage destruction through regulating 
the bioavailability and/or bioactivity of ADAMTS4 and ADAMTS5.  
1.2.4.3 Corticosteroids and Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs) 
Glucocorticoids such as prednisolone are steroidal-based drugs administered orally 
or by intra-articular injection that have immunomodulatory properties and potent 
systemic and local anti-inflammatory effects, offering another treatment option for 
both OA and RA (Figure 1.4). Their short-term use is often indicated in acute joint 
injuries, joint replacement surgery and tendonitis to suppress inflammation (190-
192). It has been suggested in RA that glucocorticoids may be just as powerful as 
biological agents such as infliximab in combination with a DMARD (193). 
Glucocorticoids are used to manage acute pain and inflammation as they inhibit 
NF-κB, a potent mediator of cytokine signalling. Given their immunosuppressive 
properties, glucocorticoid treatment is also likely to lead to the suppression of 
ADAMTS4 and ADAMTS5 aggrecanase activity (Figure 1.3). Their disease 
modifying properties have become more apparent recently, with evidence 
suggesting they slow the radiographic progression of the disease, even after halting 
treatment (193). However, although often quite effective, their side effects are 
problematic and include weight gain, osteoporosis, immunosuppression, altered 
glycaemic control, glaucoma, fractures, muscle wasting and hypertension, which 
are mitigated by using the lowest possible dose for the shortest time period.  
NSAIDs such as aspirin (acetylsalicylic acid), ibuprofen, naproxen and mobic are 
recommended as the first-line of treatment in inflammatory arthritis patients due to 
their pain and stiffness relieving properties, but they are also an effective treatment 
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for OA. These agents inhibit cyclooxygenase (COX), which catalyses the synthesis 
of prostaglandins. Recent evidence demonstrates celecoxib, a selective COX-2 
inhibitor, could diminish cyclic tensile strain by decreasing ADAMTS5 and 
increasing AGC (aggrecan) expression in porcine mandibular chondrocytes (194), 
suggesting NSAIDs may provide dual inhibition of inflammation and cartilage 
destruction. However, there are concerns about their long-term safety and efficacy 
due to their associated toxicity and dose-dependent adverse effects including 
gastrointestinal ulcer perforation and bleeding, renal impairment and platelet 
dysfunction. 
1.2.4.4 Statin therapy: an emerging RA and OA arthritis treatment 
Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, include 
atorvastatin, mevastatin, pravastatin and simvastatin, that are prescribed for 
cholesterol reduction and are effective in reducing cardiovascular morbidity and 
mortality (195). However, they also appear to have pleiotropic actions independent 
of their cholesterol-lowering properties, such as anti-inflammatory effects, as 
demonstrated in both experimental models of arthritis as well as in human trials 
(196, 197).  
There is evidence to suggest that statins have strong anti-inflammatory effects in 
RA. Simvastatin decreased articular macrophage infiltration and suppressed bone 
destruction in an RA rat model (198). Furthermore, simvastatin inhibited the 
migration and invasion of fibroblast-like synoviocytes by preventing the activation 
of RhoA, a small GTP binding protein known to activate NF-κB, thereby 
identifying it as a novel therapeutic agent for RA (199). A prospective study in RA 
patients demonstrated 20 mg/day of simvastatin was safe and elicited anti-
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inflammatory effects with mild clinical improvements in measures such as swollen 
joint counts and DAS28 scores (200). Disease activity also improved in RA patients 
undertaking a methotrexate regimen in combination with atorvastatin, with 
evidence that inflammatory cytokines such as TNF-α were decreased systemically 
providing a potential underlying mechanism for these effects (201). A different trial 
of atorvastatin in RA patients revealed improvement in DAS28 scores, as well as a 
decrease in C-reactive protein and erythrocyte sedimentation (202).  
However, conflicting evidence exists regarding the effects of statins. They have 
been found to accelerate the effect of collagen type II-induced arthritis in mice 
(203). Furthermore, statins may also induce a pro-inflammatory response in 
peripheral blood mononuclear cells by activating IL-18 and caspase-1 (204). 
Although rosuvastatin has been shown to reduce C-reactive protein in RA patients, 
this effect did not correlate with an improvement of overall RA disease activity 
(205). Therefore, statins may have both anti- and pro-inflammatory effects 
depending on the form and progression of the disease, the type of statin prescribed 
and whether the patient is undertaking a multiple-drug regimen. Further 
investigation into the effects of statins is required in RA to clarify whether they are 
clinically effective anti-inflammatory treatments in human trials and whether a 
corresponding reduction in aggrecanase activity in RA is apparent. 
In human OA chondrocyte cultures, atorvastatin produced a significant reduction 
in IL-1β and MMP13, as well as an increase in AGC and COLIIA1 (collagen IIA1), 
indicating that atorvastatin may have chondroprotective and anti-inflammatory 
effects (206), which may be relevant in the treatment of OA. This was also 
demonstrated with mevastatin, which showed reduced inflammatory cell 
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infiltration and reduced expression of Il-1β and matrix-degrading enzymes (Mmp3 
and Mmp13) in a rabbit model of experimental OA (207). Furthermore, in a rat 
model of mechanically induced knee OA, simvastatin produced anti-inflammatory 
and immunomodulatory effects via inhibition of MMP3 expression (208). 
Therefore, several types of statins may not only have anti-inflammatory effects, but 
may also exert chondroprotective effects in both OA and RA patients.  
1.2.4.5 Small Molecule Inhibitors of the Aggrecanases ADAMTS4 and 
ADAMTS5  
Although several treatment options of varying efficacy are currently available for 
arthritis, many alternatives are currently being explored, especially those that 
selectively inhibit MMP collagenases and ADAMTS aggrecanases. Synthetic 
broad-spectrum MMP inhibitors such as batimastat and marimastat showed 
promise as anti-cancer therapies in the 1990’s, leading to reduced tumour growth 
and spread in various animal models (209-214). However, phase II clinical trials of 
these inhibitors revealed severe toxicity as well as a tendency to advance disease 
progression in several studies (215-218). This has led to a more targeted approach 
to developing MMP and ADAMTS inhibitors as therapeutic interventions in 
disease.    
TIMPs are endogenous inhibitors of MMP and ADAMTS proteinases, and are 
essential to homeostasis of the joint and proper matrix turnover. There are four 
mammalian TIMPs, designated TIMP1-4. TIMP3 has a broad profile of inhibition 
that includes ADAMTS4 and ADAMTS5, unlike the other TIMPs that are more 
specific. TIMP3 acts as a tumour suppressor and inhibitor of angiogenesis (219). 
Moreover, Timp3-/- mice showed enhanced TNF signalling and increased serum IL-
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6 levels (220), indicating a key role for TIMP3 in innate immunity. Furthermore, 
Timp3-/- mice presented with an increased inflammatory response to antigen-
induced arthritis and increased aggrecan and collagen II degradation with age (221, 
222). TIMP3 may therefore represent a suitable therapeutic treatment for arthritis 
patients to not only suppress innate inflammatory cytokines in arthritis but also the 
ADAMTS4 and ADAMTS5 enzymes. Their lack of selectivity precludes them as 
an adequate treatment option in their native form. However, truncated TIMP (N-
TIMP3), lacking its C-terminal domain, was a potent endogenous inhibitor of 
ADAMTS4 and ADAMTS5 with inhibition also demonstrated towards MMP1, 
MMP2 and to a lesser extent, MMP3 (223). Furthermore, the thrombospondin type-
1 repeats of ADAMTS4 and ADAMTS5 promote binding with N-TIMP3 (224) 
providing further evidence that N-TIMP3 may effectively inhibit ADAMTS4 and 
ADAMTS5 with high affinity. Moreover, engineering the reactive site through 
amino acid substitutions within the N-terminus of N-TIMP3 has increased 
selectivity towards ADAMTS4 and ADAMTS5 ablating off-target MMP inhibition 
(225), suggesting that further modifications of TIMPs may lead to a powerful and 
specific therapeutic in the future.  
The need to develop novel and selective aggrecanase inhibitors has become 
increasingly essential to arthritis research. A series of (2R)-N4-hydroxy-2-(3-
hydroxybenzyl)-N1-[(1S,2R)-2-hydroxy-,3-dihydro-1H-inden-1-yl] 
butanediamide derivatives have previously been developed as potent and selective 
inhibitors of aggrecanase activity (226). A 3-hydroxyl group on one of the 
inhibitors achieved selectivity through hydrogen bonding with a threonine residue 
in the S1 pocket of ADAMTS5. This threonine is also present in ADAMTS4, 
however, a valine residue replaces this threonine in the active site of most MMPs, 
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thereby achieving some selectivity towards the aggrecanases (227). Recently, a 
series of novel achiral N-hydroxyformamide inhibitors of ADAMTS4 and 
ADAMTS5 have emerged, which showed high selectivity and potency in vitro 
(228). In addition, a new family of non-hydroxamic inhibitors, which display a 
1,2,4-triazole-3-thiol scaffold as a putative zinc-binding group, have shown a 
reasonable level of selectivity towards ADAMTS5 (229).  
Among N-((8-Hydroxy-5-substituted-quinolin-7-yl)(phenyl)methyl)-2-
phenyloxy/amino-acetamide compounds, four demonstrated greater ADAMTS5 
potency and selectivity compared to both ADAMTS4 and MMP-13 (230). In 
addition, 5-((1H-Pyrazol-4-yl)methylene)-2-thioxothiazolidin-4-1 inhibitors have 
also shown good selectivity of ADAMTS5 over ADAMTS4 (231). Another series 
of compounds, α-glutamic acid scaffold based 4-(benzamido)-4-(1,3,4-oxadiazol-
2-yl) butanoic acids have also been synthesised and have shown the ability to 
inhibit the activity of both ADAMTS4 and ADAMTS5 (232). In addition, a series 
of 1-sulfonylaminocyclopropanecarboxylates and N-substituted sulfonylamino-
alkanecarboxylates were demonstrated to be potent ADAMTS5 inhibitors with 
good selectivity compared to MMPs such as MMP1 (233). More recently, potent 
and selective novel ADAMTS5 inhibitor scaffolds lacking a zinc-binding motif 
were designed, which instead contained a 1,3,5-triazine core (234). The 
aggrecanase inhibitor AGG-523, which inhibits both ADAMTS4 and ADAMTS5 
from Wyeth pharmaceuticals (now a part of Pfizer) has undergone clinical trials in 
anticipating treating OA, and may become a new osteoarthritis drug in the 
foreseeable future (235). As an alternative approach, an ADAMTS5 antibody 
(CRB0017) ameliorated OA progression in a spontaneous OA mouse model (236). 
Furthermore, in human cartilage explants and cynomolgus monkeys, treatment 
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using a humanised ADAMTS5 selective monoclonal antibody (GSK2394002) 
resulted in suppression of ARGS neoepitope release (237). Combined, these data 
provide proof-of-principle evidence that inhibiting the aggrecanases, especially 
ADAMTS5, might be a promising therapeutic.   
1.3 Rationale 
The ADAMTS proteoglycanases have similar modes of secretion and substrate 
specificity. Therefore, an understanding of their specific fundamental biochemistry 
is required to determine their functional roles in diseases such as arthritis and 
cancer. Furthermore, understanding the roles of the ADAMTS proteoglycanases 
during vertebrate development is vital, as it may improve knowledge of the 
biological mechanisms underpinning diseases in which ADAMTS 
proteoglycanases are key contributors.  
ADAMTS15 is currently largely uncharacterised; however, its potential role as a 
tumour suppressor in breast and colon cancer makes it an important 
proteoglycanase in disease. A detailed analysis of its biochemistry, as well as its 
expression in adult and embryonic tissue, is of crucial importance to understand 
how it may be dysregulated in cancer.  
ADAMTS5 is a widely expressed proteoglycanase that has roles in development of 
cardiac valves, pentameric digits and skeletal muscle. However, elucidating further 
early developmental functions in the mouse is challenging, given the overlapping 
roles of the ADAMTS proteoglycanases. Other vertebrate models may enable 
further analysis given the high conservation of the primary amino acid sequence 
across vertebrates.   
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Optimisation and individualisation of treatment strategies for arthritis patients is 
also required, as current treatments continue to fail in efficacy and often lead to 
serious side effects in a significant number of arthritis patients. Further research 
into prospective treatments, as well as into the mechanisms underlying joint 
destruction, is imperative. It is clear that current and emerging therapeutics that 
could indirectly or directly inhibit the ADAMTS aggrecanases, ADAMTS4 and 
ADAMTS5, may lead to inhibition of cartilage degradation and inflammation in 
arthritis. There is a substantial body of evidence to suggest that statins may have 
pleiotropic anti-inflammatory and chondroprotective effects in arthritis that may be 
mediated through inhibition cartilage-degrading enzyme activity. Further evidence 
is required to elucidate the mechanisms by which statins inhibit cartilage 
destruction in arthritis and whether this is mediated through the ADAMTS 
aggrecanases.  
1.4 Hypotheses 
The first hypothesis underlying this thesis was that ADAMTS15, a proteoglycanase 
of unknown function but closely related to ADAMTS5, would have an overlapping 
biosynthesis and activation mechanism to that of the other proteoglycanases, and 
represent an extracellularly secreted versicanase. In addition, ADAMTS15 was 
hypothesised to have a wide expression pattern in the mouse that would overlap 
with patterns of other proteoglycanases and versican. The second hypothesis 
underlying this thesis was that ADAMTS5, a well-characterised proteoglycanase 
in development and disease, would have undiscovered roles during early 
developmental processes such as gastrulation and somitogenesis, given its wide 
expression pattern in the mouse, which could be uncovered in other vertebrate 
models. The third and final hypothesis underlying this thesis was that statins would 
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inhibit cartilage destruction in arthritis patients through decreasing pro-
inflammatory cytokine levels and sulphated glycosaminoglycan levels through a 
decrease in aggrecan cleavage neoepitope production by the aggrecanases 
ADAMTS4 and ADAMTS5.  
1.5 Aims 
The first aim of this thesis was to define the mode of secretion and the substrate 
specificity of ADAMTS15 in vitro, as well as its in vivo expression pattern in the 
mouse. The second aim of this thesis was to examine the consequences of adamts5 
silencing in zebrafish, assessing gross physiology and differential expression 
patterns of important developmental markers during gastrulation and somitogenesis 
to determine the role of ADAMTS5 during the early stages of vertebrate 
development. The third aim of this thesis was to assess levels of sulphated 
glycosaminoglycans, aggrecan cleavage and pro-inflammatory cytokines in the 
synovial fluid from arthritis patients to determine whether statins improved patient 
outcomes through ADAMTS4 and ADAMTS5 inhibition compared to other 
arthritis therapies. 
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2 Methods 
2.1 Ethics 
The Deakin University Animal Welfare Committee (DUAWC) approved all 
experiments performed on animals in accordance with the National Health and 
Medical Research Council ‘Guidelines for Care and Use of Animals in Research’. 
Zebrafish DUAWC ethics numbers were A29/2011 and G14/2013. Mouse 
DUAWC ethics numbers were A79/2010 and G34/2013. Human ethics were 
approved by the Deakin University Human Research Ethics Committee 
(DUHREC) under the ethics number 2012-122, with all patients giving their 
informed consent for the use of their synovial fluid as part of the study. 
2.2 Protein Methods 
2.2.1 Cell Culture, Transfection and Protein Sample Preparation 
HEK293T and COS-7 cells (ATCC, Manassas, USA) were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10% foetal bovine serum (FBS) 
(Invitrogen, Mulgrave, Australia) in 5% CO2 at 37°C (HERAcell 150i, Thermo 
Scientific, Scoresby, Australia). Cells were seeded at 400,000 cells per well in 6-
well plates (Corning Life Sciences, Mount Martha, Australia). Constructs encoding 
full-length Adamts15, its respective deletion constructs or site-directed mutants 
(constructed by Dr Daniel McCulloch), full-length Adamts5 (13), ProCat Adamts5 
(13), ProCat Adamts9 (16), or a full-length V1 versican construct (kindly provided 
by Professor Dieter Zimmerman) were added to serum-free DMEM containing 
Lipofectamine-2000 (Invitrogen). The Lipofectamine/DNA (1 or 2 μg/well) 
complex was added to each well in 2 ml of growth medium. After 4–5 h, growth 
medium was removed, and 1 ml of serum free DMEM per well was added to the 
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cells. Cells were treated with or without the synthetic furin inhibitor decanoyl-Arg-
Val-Lys-Arg-chloromethyl ketone (dec-RVKR-cmk) (Enzo LifeSciences, Exeter, 
UK), heparin sodium salt (Sigma-Aldrich, Castle Hill, Australia), or PNGaseF 
(New England Biolabs, Ipswich, USA) or treated with or without 10 and 20 μM 
atorvastatin (Sigma-Aldrich) (238-240). Forty eight hours later, the conditioned 
media (CM) was collected, and cells were harvested in ice-cold 1 x PBS with a cell 
scraper from which cell lysate (CL) was extracted using 1% Triton X-100 in 150 
mM NaCl, 20 mM Tris-HCl, pH 7.5, containing EDTA-free complete protease 
inhibitor mixture (Roche Applied Science, Castle-Hill, Australia). Cell lysates were 
also extracted from 24 hpf embryos. Resultant CM and CL samples were stored at 
-80°C until further processing. Even sample loading (40 μl CM or 20 μl CL) was 
used for Chapter 3 and a BCA protein assay kit (Thermo Scientific) was used to 
determine even protein loading for Chapter 5 with 20 μg of protein loaded into each 
well. Briefly, 0-2000 μg/mL concentrations of bovine serum albumin (BSA) were 
prepared as standards for the reaction. Duplicates of each standard and sample was 
used in the microplate with 25 μl used in each well. Working reagent (200 μl) was 
added to each well and mixed thoroughly for 30 sec on a plate shaker prior to 
incubating for 30 min at 37 °C. The plate was cooled and then absorbance was 
measured at 562 nm.  
2.2.2 Western Blotting 
Standard Western blotting procedures were used (241) to analyse recombinant 
ADAMTS15 protein following transfection or to analyse ADAMTS5 from 
zebrafish embryos. Briefly, protein samples were incubated in Laemmli sample 
buffer (242) and boiled for 3 min at 95°C, placed on ice for 5 min and centrifuged 
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for 15 sec at 3000 rpm. Protein samples (40 μl CM or 20 μl CL) were typically run 
on 6%, 7.5% or 10% (w/v) Bis/Tris acrylamide gels (Bio-Rad, Gladesville, 
Australia) and separated by SDS-PAGE under reducing conditions alongside the 
Precision Plus protein standard (Bio-Rad). After transfer to PVDF membrane 
(LICOR Biosciences, NE, USA), non-specific sites were blocked with 5% skim 
milk in TBS-T (150 mM NaCl, 20 mM Tris-HCl, pH 7.5 + 0.1% Tween 20).  Anti-
Myc clone 9E3 (Sigma-Aldrich) or anti-ADAMTS15 propeptide (catalogue no. 
ab45047; Abcam, Melbourne, Australia) antibodies were typically used at 1:5,000 
to detect recombinant proteins in CL and CM or the polyclonal rabbit anti-
propeptide ADAMTS5 antibody (catalogue no. ab39203-100, Abcam) and the anti-
C-terminal ADAMTS5 antibody (catalogue no. AB19170; Merck Millipore, 
Bayswater, Australia) (both used at 1:5,000) were used to detect ADAMTS5 in 
zebrafish embryos or in statin-treated cells. The anti-V0V1 (catalogue no. PA1-
1748A, Thermo Scientific) antibody (1:500) was used to detect cleaved versican 
(DPEAAE epitope; coined versikine), and anti-glycosaminoglycan-β (catalogue 
no. AB1033, Merck Millipore) antibody (1:5,000) were used to detect full-length 
V1 versican. Secondary antibodies (anti-rabbit IR800 (Sapphire Bioscience, 
Waterloo, Australia) or anti-mouse IR680 (Sigma-Aldrich) were incubated for 1 h 
at room temperature (both used at 1:10,000), followed by TBS-T washes. The 
Odyssey (LICOR, Lincoln, USA) imaging system was used to detect 800 nm 
(green) and 700 nm (red) IR antibodies. Typical settings were: resolution 169 μm, 
medium quality, 3.0 mm focus offset, and an intensity level of 5 for each 700 and 
800 nm scans. Most Western blots were detected using chemiluminescence; in 
these cases, the same procedure was followed except the secondary antibodies (goat 
anti-rabbit or goat anti-mouse at 1:10,000) were conjugated with horseradish 
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peroxidase (Dako, North Sydney, Australia), and the signal was detected on film 
(Amersham) using ECL or ECL-prime (GE Healthcare, Silverwater, Australia). 
Coomassie blue staining or an anti-GAPDH (Merck Millipore) was used to assess 
levels of loading as described previously in both CL and CM (243, 244) at 1:10,000 
to confirm even protein loading.     
2.2.3 Cell-surface Biotinylation 
Cell-surface biotinylation was performed as described previously for the detection 
of ADAMTS9 ProCat on the cell surface (245). Briefly, COS-7 cells transfected 
with full-length Adamts15 (Adamts15-I), Adamts15 ProCat (Adamts15-VII), or 
Adamts9 ProCat (positive control) (245) were harvested with or without trypsin and 
washed in 3 x 1.5 ml ice-cold PBS, with re-suspension and centrifugation at 1000 
rpm for 5 min between each wash. Next, 10 μl of 100 mg/ml stock EZ-Link Sulfo-
NHS-Biotin (Thermo Scientific) in PBS was added and incubated at 4°C for 30 
min. One wash in 50 mM Tris-HCl (pH 8.0) and 3 washes in PBS were performed 
with re-suspension and centrifugation occurring between each wash (as above). 
Cells were lysed in 1% Triton X-100 in 150 mM NaCl, 20 mM Tris-HCl, pH 7.5, 
containing EDTA-free complete protease inhibitor mixture (Roche Applied 
Science, Castle-Hill, Australia) on ice for 30 min and centrifuged for 10 min at 
13,000 rpm at 4°C. Biotinylated proteins were captured with 50 μl streptavidin-
agarose (Sigma-Aldrich) and agitated overnight at 4°C then washed in a series of 
50 mM Tris-HCl and PBS washes with re-suspension and centrifugation between 
each wash (as above). Samples were eluted by boiling in Laemmli sample buffer 
prior to Western blotting. Untransfected cells were included in the procedure as a 
negative control. 
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2.2.4 Versicanase Assays  
Versicanase assays were performed essentially as described previously (13, 16, 34, 
243). Briefly, 50 μl of CM was combined with 50 μl of CM containing versican 
(V1 splice variant) and incubated at 37°C for 4, 9, 12, 16 and 24 h. After boiling 
and incubation on ice, 5 mU chondroitinase ABC (Seikagaku, Tokyo, Japan) was 
added per reaction to the samples and incubated for 2 h at 37°C to ensure 
glycosaminoglycan chains were cleaved for effective resolution of the core protein 
by SDS PAGE as described above.  
2.2.5 Immunofluorescence 
Immunofluorescence was performed essentially as described previously (34, 74) 
on paraformaldehyde-fixed paraffin-embedded sections (3-5 μm) with the anti-
ADAMTS15 propeptide antibody (1:1000). The anti-V0V1 (catalogue no. PA1-
1748A, Thermo Scientific) antibody (1:500) was used to detect cleaved versican 
(DPEAAE epitope; coined versikine), and anti-glycosaminoglycan-β (catalogue 
no. AB1033, Merck Millipore) antibody (1:5,000) was used to detect full-length 
V1 versican with corresponding Alexa fluor FITC-conjugated or Alexa fluor 597-
conjugated goat anti-rabbit immunoglobulin (Molecular Probes, Scoresby, 
Australia) used as the secondary antibodies typically at 1:2,500. In all cases, 
Normal Goat Serum (NGS; Dako) was used to block non-specific antigen binding 
sites prior to incubation with the primary antibody. For co-localisation with 
hyaluronan, biotinylated hyaluronan binding protein (a kind gift from Associate 
Professor Amanda Fosang) was used in conjunction with streptavidin-FITC 
(Sigma-Aldrich) for detection. The immunogenic peptide (catalogue no. Ab45243, 
Abcam) corresponding to the anti-ADAMTS15 epitope was used as a blocking 
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control. Nuclei were counterstained and slides mounted with Vectashield-DAPI 
mounting medium (Vector Laboratories, Burlingame, CA). Images were obtained 
as above on an automated confocal microscope (Fluoview FV10i; Olympus, 
Notting Hill, Australia) using FITC (excitation 495 nm/emission 519 nm) alongside 
the DAPI channel (excitation 359 nm/emission 451 nm) to visualise the nuclei. The 
manufacturer’s default imaging software package (Fluoview V2.1B) was used for 
image analyses.  
Whole-mount antibody labelling was performed on staged zebrafish embryos with 
polyclonal rabbit anti-propeptide ADAMTS5 (catalogue no. ab39203-100, Abcam) 
at 1:200 and monoclonal rabbit anti-pSmad3 (catalogue no. 9520, Cell Signalling 
Technologies, Beverly, USA) or anti-pSmad1/5/8 (catalogue no. 9511S, Cell 
Signalling Technologies) at 1:50, followed by anti-rabbit Alexa fluor 594 
secondary antibody at 1:500 (Life Technologies, Scoresby, Australia). 
Histochemical methods were performed as previously (246). Briefly, embryos were 
fixed in 4% PFA (PFA; ProSciTech, Kirwan, Australia) / PBS overnight at 4 °C 
and washed 5 x 5 min in PBS-T (1 x PBS + 1% TritonX-100). Embryos were 
blocked in 10% NGS (Dako) in PBS-T for 1 h and replaced with primary antibodies 
(as above) diluted in PBS-T + 1% NGS overnight at 4 °C. Several washes in PBS-
T were performed prior to and following the addition of secondary antibody 
overnight at 4°C. Phalloidin staining was performed following a published protocol 
(247). For washing steps, 2% TritonX-100 was used and phalloidin Alexa fluor 568 
(Life Technologies) was used at 1:20 in 10% NGS / PBS-T. Zebrafish were imaged 
in 70% glycerol / PBS. 
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2.3 Zebrafish Methods 
2.3.1 Zebrafish Lines, Maintenance and Collection 
Adult wild-type and Tg(acta1:mCherry)pc4 zebrafish (Danio rerio) (248) (kindly 
provided by Professor Peter Currie and Dr Thomas Hall) were maintained in an 
Aquatic Habitats (Beverly, USA) aquarium system at 28.5°C on a 13 h / 11 h light 
/ dark cycle and were fed 2-3 times daily on a standard diet of Otohime Hirame S1 
granules (Aquasonic, Wauchope, NSW) and enriched instar II Artemia (brine 
shrimp).  Embryos were obtained by adult mating trios (1 male + 2 females) or 
using a mass embryo production system (MEPS) (Aquatic Habitats) and kept at 
28.5°C in system water containing 0.00005% (w/v) methylene blue (Sigma-
Aldrich, Castle Hill, Australia) and replaced with 0.003% (w/v) 1-phenyl-2-thio-
urea (PTU; Sigma-Aldrich) by 16 hours post fertilisation (hpf) to prevent 
pigmentation. Embryos were staged according to standard protocols (137) and 
humanely killed in 0.01 mg/ml benzocaine (Sigma-Aldrich) prior to fixation in 4% 
PFA/PBS.  
2.3.2 Embryo Microinjection 
Morpholino antisense oligonucleotides (MOs; Gene Tools, Philomath, USA) 
targeting the ATG start codon 
(5’ATGCTGTCGAAATTACAGGAGTTTGGCGCGTAT) and the exon 2/3 
boundary 
(5’CTATCATTGAGGACGACGGCCTGCACGCTGCCTTCACTGTGGCTCAT
GAGATC) position within the zebrafish adamts5 mRNA (GenBank: JF778846.1) 
were used to ablate ADAMTS5 during development. MOs were used at an optimal 
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concentration of 1 mM (previously optimised by Mr Adam Smith under the 
supervision of Dr Daniel McCulloch) in 1 x Danieau’s buffer (50 mM NaCl, 0.7 
mM KCl, 0.4 mM MgSO4, 0.6 mM CaCl, 5 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid), pH 9.0) and 0.5% (w/v) phenol red with 5 nl 
microinjected per embryo at the 1-4 cell stage (140). Capped antisense RNA 
encoding full-length wild-type or catalytically-inactive (E411A) ADAMTS5 (13) 
were synthesised using the T7 mMessage mMachine kit (Ambion, Scoresby, 
Australia) and microinjected at 200 pg/5 nl into one-cell stage embryos (249). 
2.3.3 Pharmacological Treatments 
For TGF-β rescue, embryos were treated with 100 pM activated recombinant 
human TGF-β (R&D Systems, Minneapolis, USA) or 100 pM recombinant 
zebrafish bone morphogenetic protein-4 (BMP4; R&D Systems) in 4 mM HCl and 
1 mg/ml bovine serum albumin (BSA; Sigma-Aldrich) and the corresponding 
vehicle controls in system water at 6 hpf and fixed in 4% PFA / PBS at 8 hpf. For 
other studies, injected embryos were treated with 5 and 50 μM cyclopamine 
(Sigma-Aldrich) and the corresponding vehicle control (dimethylsulfoxide 
DMSO), and Smoothened (Smo) agonist (Merck Millipore) at 10 μM and 20 μM 
at 5.5 hpf and fixed at 12 hpf in 4% PFA/PBS. 
2.3.4 Whole-mount in situ Hybridisation  
Whole-mount in situ hybridisation (WISH) was performed as per previous 
protocols (250). Briefly, fixed embryos (stored at -20°C in 100% methanol 
following 4% PFA/PBS fixation and dechorionation with fine forceps) were 
rehydrated in a series of 5 min methanol washes in 50% methanol, 30% methanol 
and 1 x PBS-T (0.1% Tween-20 (Sigma-Aldrich) prior to post-fixation for 20 min 
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in 4% PFA/PBS. Embryos were pre-hybridised at 70°C with HYB- (100 ml: 50 ml 
formamide, 25 ml 20 x SSC, 0.1 ml Tween-20, 25 ml mH2O) and HYB+ (as for 
HYB-, with 5 mg/ml ribonucleic acid (Sigma-Aldrich)).  
The following antisense digoxigenin-labelled mRNA probes were synthesised: 
shha and myod (251), no-tail (252) and patched1 (253). Briefly, plasmid constructs 
were propagated in Escherichia coli (DH5α competent cells; Life Technologies) by 
heat shock at 42°C with LB broth (400 ml: 4 g tryptone, 2 g yeast extract, 4 g NaCl, 
400 ml milli-Q water) and recovery at 37°C for 1 h, then spread onto LB agar plates 
(as for LB broth, with 6 g agar) and incubated overnight at 37°C. Colonies were 
picked and placed into LB broth with 100 μg/ml ampicillin (Sigma-Aldrich) 
overnight and purified using PureLink Quick Plasmid Miniprep Kit (Life 
Technologies). Following restriction enzyme digest, probes were synthesised using 
an in vitro transcription kit (Roche Applied Science).  
Probes were diluted at 1:100 with HYB+ and incubated with embryos overnight at 
70°C. Probe was removed in a series of washes at 70°C: 30 min with 50% 
formamide / 2 x SSC-T (Saline Sodium Citrate + 0.1% Tween-20), 60 min 50% 
formamide / 2 x SSC-T, 15 min 2 x SSC-T, 2 x 15 min 0.2 x SSC-T, 3 x 5 min 1 x 
PBS-T. Embryos were then incubated in blocking buffer (100 ml: 95 ml 1 x PBS-
T, 5 ml heat-inactivated foetal bovine serum (FBS; In Vitro Technologies, Noble 
Park North, Australia), 0.02 g BSA) for 2 h and in 1:5,000 anti-digoxigenin 
antibody (Roche Applied Science) in blocking buffer overnight at 4°C. A further 8 
x washes in blocking buffer were performed at 30 min each and 3 x 5 min with 
staining buffer (1 M Tris (pH 9.5), 5 M NaCl, 0.1% Tween-20, 0.1% levamisole 
and mH2O) followed by an incubation in nitro-blue tetrazolium chloride (NBT)/ 5-
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bromo-4-chloro-3'-indolyphosphate p-toluidine salt (BCIP) (Roche Applied 
Science) at 1:50 in staining buffer. Zebrafish were imaged in 70% glycerol/ PBS 
on an Olympus MVX10 Fluorescence MacroZoom, Olympus DP73 colour camera 
using Olympus CellSens Dimensions software. 
2.4 Mouse Methods 
2.4.1 Breeding  
For collection of embryos, timed overnight matings between adult (at least 6 weeks 
of age) Adamts5 and Adamts15 or wild-type mice (Animal Resource Centre, Perth, 
Australia) were confirmed by the observation of a vaginal plug before 9:00 am the 
following morning, at which time the embryonic age was designated as E0.5 days 
post-coitus (dpc) as per previous studies (34, 74). Mice were humanely killed in a 
CO2 chamber, as per Deakin University standard operating procedures, and the 
embryos harvested for further processing. 
2.4.2 Whole-mount in situ Hybridisation  
Embryos were fixed in 4% PFA/ PBS at 4°C overnight, washed in PBS-T (1 x PBS 
+ 1% Tween-20) for 5 min, dehydrated in increasing concentrations of methanol in 
PBS-T (25%, 50%, 75%, 100%) for 5 min each and washed again in 100% 
methanol for 5 min before storage at -20°C. Samples were rehydrated in a 75%, 
50% and 25% methanol/ PBS-T series and washed twice in PBS-T for 5 min each. 
Embryos were then treated with 10 μg/ml proteinase K in PBS-T for 5-15 min 
depending on the embryonic stage and washed in 2 mg/ml glycine in PBS-T, 
followed by 2 x 5 min wash in PBS-T and a post-fixation step in 4% PFA and 0.2% 
glutaraldehyde in PBS-T for 20 min at RT. They were washed 2 x 5 min in PBS-T 
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then 10 min in a 1:1 solution of hybridisation solution (50% formamide, 5 x SSC 
pH 4.5, 1% SDS, 50 μg/ml yeast tRNA and 50 μg/ml heparin) in PBS-T, before 
another 10 min wash in hybridisation solution alone followed by 70°C pre-
hybridisation for at least 1 h. RNA probes were used 1:10-1:50 in hybridisation 
solution and incubated overnight at 70 °C. Embryos were washed 3 x for 30 min 
each at 70°C with pre-warmed solution I (50% formamide, 5 x SSC pH 4.5 and 1% 
SDS) then washed in pre-warmed solution III (50% formamide and 2 x SSC pH 
4.5). They were washed 3 x 5 min with TBS-T then blocked by incubation for 60-
90 min in 10% heat-inactivated sheep serum and 0.1% Boerhinger Mannheim 
blocking reagent (Roche Applied Science) in TBS-T. Anti-DIG AP antibody 
(Roche Applied Science) was used at 1/5000 in 1% sheep serum / TBS-T overnight. 
Embryos were washed in TBS-T for 3 x 5 min, 5 x 1 hr in TBST and then overnight 
in TBS-T at 4 °C with gentle rocking. 3 x 10 min washes in NTMT (100 mM NaCl, 
100 mM Tris-HCl pH 7.5, 50 mM MgCl2, 1% Tween-20, 2 mM Levamisole 
(Sigma-Aldrich)). The NTMT was replaced with 125 μg/ml BCIP and 250 μg/ml 
NBT (Roche Applied Science) in NTMT and embryos were kept in the dark for the 
colour reaction to develop. When the reaction was complete, embryos were washed 
in PBT and post-fixed in 4% PFA with 0.1% glutaraldehyde in PBS-T for at least 
an hour then were washed in 1 x PBS 2-3 times and stored in 1 x PBS until imaging.        
2.5 Human Methods 
2.5.1 Patient Selection 
The patients of the cohort for this retrospective study included 118 patients 
presenting with various arthritides but predominately RA, OA and PSA. The patient 
cohort were diagnosed and assigned treatment regimens by a consultant 
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rheumatologist within Barwon Rheumatology Clinic. The median patient age was 
60 years (18-92 years).  
2.5.2 Synovial Fluid Preparation 
Barwon Rheumatology Service, as part of routine corticosteroid injection 
treatment, collected synovial fluid from knee or shoulder joints by routine 
aspiration. Approximately 2 - 10 ml of synovial fluid per joint was collected per 
patient joint, transferred into sodium heparinised vacutainers (BD Biosciences, 
North Ryde, Australia), and stored at 4oC for up to 7 days until collection. Samples 
were transported on ice, centrifuged at 3,000 rpm for 10 min in 15 ml tubes 
(Corning Polystyrene Centrifuge Tubes) to pellet intra-articular debris. Supernatant 
were treated with 0.5 U/μl hyaluronidase (Sigma Aldrich) as per previous studies 
(254, 255). Sub-aliquots were stored at -80°C until further analyses. 
2.5.3 Sulphated Glycosaminoglycan Quantification 
Proteoglycan release into the synovial fluid was assessed using 1, 9-
dimethylemethylene blue (DMMB) dye (Sigma-Aldrich) which detects levels of 
sulphated glycosaminoglycan (GAG) binding against a chondroitin sulphate 
standard curve according to previous methods (256) with modifications. 
Concentrations of chondroitin sulphate between 0 - 60 μg/ml were used for the 
standard curve prepared from 1 mg/ml stock of chondroitin sulfate sodium salt from 
shark cartilage (Sigma-Aldrich) diluted in nuclease free water (NFW, Ambion). 
Two hundred and fifty μl of DMMB (0.016 mg/ml dimethylmethylene blue 
powder, 0.5% ethanol, 4 mg/ml sodium formate, 0.2% formic acid) was added to 
40 μl undiluted sample or 1:2 or 1:4 diluted samples. Absorbances were read on a 
microplate reader (Spectra Max 340 PC, Molecular Devices, CA, USA) using 
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SoftMax Pro software (version 4.8) at 595 nm and a reference of 655 nm was taken 
to account for background interference.  
2.5.4 Cytokine Enzyme Linked Immunosorbent Assays (ELISAs) 
Inflammatory cytokines IL-1α, IL-1β, TNF-α and IL-6 were quantified in synovial 
fluid using the sandwich ELISA technique in duplicate similarly to previous 
protocols (257)  and according to manufacturer’s instructions (elisakit.com, 
Melbourne, Australia) against their corresponding standard curves (0 - 1000 pg/ml 
IL-1α, 0 - 200 pg/ml IL-1β, 0 - 1000 pg/ml TNF-α and 0 - 2000 pg/ml IL-6) at room 
temperature (RT). Negative controls, standards and samples were incubated in 
duplicate in the 96 well plate containing the capture antibody for 2 hours then 
washed 4 x with 250 μl wash buffer before replacing with 100 μl of 250 ng/ml 
biotin labelled detection antibody for 2 h. Washing steps were repeated and 100 μl 
of freshly diluted (0.2%) streptavidin-HRP conjugate was incubated for 45 min. 
Additional washing steps (5 x) were performed prior to the addition of 100 μl 
3,3',5,5'-Tetramethylbenzidine (TMB) substrate in the dark for approximately 15 
min or until blue colour change had developed then 50 μl of STOP solution was 
added with absorbance  read on a microplate reader at 450 nm (xMark Microplate 
Absorbance Spectrophotometer, Bio-Rad).  
2.5.5 Aggrecanase ELISAs 
A sensitive aggrecanase (ADAMTS4 and ADAMTS5) activity sandwich ELISA 
was performed according to manufacturer’s instructions to quantitate the 
aggrecanase-generated C-terminal 374ARGS fragment (MD Biosciences, Zurich, 
Switzerland). Briefly, an aggrecanase module was performed whereby standards of 
serial dilutions of ADAMTS4 (0.062 nM - 2 nM) were incubated with aggrecan as 
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a standard of aggrecanase activity. Serial dilutions of ARGSVIL peptide (0.022 nM 
- 1.4 nM) were also used as standards to determine the amount of aggrecanase 
required to generate a known quantity of ARGSVIL. Sandwich ELISA was 
performed for samples in duplicate as per previous protocols (257). Briefly, the 
substrate inhibitor mixture was prepared by adding 500 μl 1 μM aggrecan-IGD, 
500 μl inhibitor solution and 3.75 ml reaction buffer. Next, 95 μl of substrate-
inhibitor mixture was pre-incubated for 5 min at 37°C prior to adding 5 μl 
ADAMTS4 standards and were incubated for 15 min at 37°C. Reactions were 
stopped by adding 150 μl of EDTA dilution buffer. Each standard and sample was 
pipetted into each well at 100 μl each and incubated at 25°C for 90 min in the dark 
on a shaker. Wells were aspirated and washed with wash buffer three times. The 
wells were incubated for 90 min at 25°C in the dark and on a shaker in antibody-
peroxidase conjugate and washed a further 5 times in wash buffer. The TMB 
detection solution (100 μl) was added to wells and incubated for 30 min in the dark 
prior to the addition of 100 μl sulphuric acid to stop the reaction. Microtiter plates 
were read on a microplate reader at 450 nm with a reference filter of 620 nm (xMark 
Microplate Spectrophotometer; Bio-Rad) using SoftMax Pro software (version 5; 
Sunnyvale, USA). 
2.6 Statistics 
To investigate correlations between age and S-GAG (μg/ml) levels in patient 
synovial fluid, the Kruskal-Wallis test was used in GraphPad Prism 4 (La Jolla, 
USA) whereby patients were divided into three groups according to age; senior 
(61+), middle (31-60) and young (18-30). Linear regression was performed to 
determine correlation between age and S-GAG levels, as well as DAS28 and S-
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GAG levels. Average of DMMB or ELISA data duplicates were used to investigate 
the significance of each treatment group in relation to drug treatment and type of 
arthritis using the Mann-Whitney U Test. Significance was set at P-value ≤0.05. 
Two-tailed paired t-tests were performed between all treatment groups compared 
to the respective control groups in the zebrafish study. Significance was achieved 
at a 95% confidence interval and a P-value ≤0.05, with Gaussian distribution 
assumed in all cases. All statistics were performed using either GraphPad Prism 4 
(La Jolla, USA) or SPSS Statistics 4.0 (IBM, St Leonards, Australia). 
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3 Biosynthesis and Expression of A Disintegrin-like 
and Metalloproteinase Domain with 
Thrombospondin-1 Repeats-15 
The majority of the results from this Chapter have been published in the article 
entitled: Biosynthesis and Expression of a Disintegrin-like and 
Metalloproteinase Domain with Thrombospondin-1 Repeats-15 by Carolyn M 
Dancevic*, Fiona W Fraser*, Adam D Smith, Nicole Stupka, Alister C Ward and 
Daniel R McCulloch. Journal of Biological Chemistry. 2013; 288(52):37267-76. 
*Joint first-authorship. The contributions of the co-authors are stated within the text 
as appropriate.  
3.1 Expression of Adamts15 Deletion Constructs in HEK293T and 
COS-7 Cells 
To examine the biosynthesis, activation and substrate recognition of ADAMTS15, 
constructs encoding C-terminally Myc/His-tagged mouse Adamts15 were 
generated (Figure 3.1A; performed by Dr Daniel McCulloch) and expressed as 
recombinant proteins in both HEK293T and COS-7 cells. The resultant cell lysate 
(CL) and conditioned media (CM) were analysed by Western blot. All constructs 
were efficiently detected in cell lysates of HEK293T cells and COS-7 cells 
(performed by Ms Fiona Fraser). Using the anti-Myc antibody, full-length 
ADAMTS15 and each deletion mutant appeared at the predicted molecular weight 
of the zymogen in the CL (Figure 3.1B, top panel). GAPDH was used a loading 
control in CL (Figure 3.1B, second panel). In the corresponding CM, deletion 
mutants ADAMTS15-V, VI, and VII appeared strongly at both the predicted 
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molecular weights of the zymogen and corresponding mature proteins, indicating 
the propeptide had been proteolytically processed extracellularly (Figure 3.1B, 
third panel; asterisks indicate mature proteins). GAPDH was used as loading 
control for CM (Figure 3.1B, bottom panel). Mature forms of full-length 
ADAMTS15 and the remaining deletion mutants were less apparent despite 
additional attempts to concentrate the medium (data not shown), although 
subsequent Western blots using ECL prime and long exposure times facilitated 
their detection (see below). Next, serum-free media ± heparin sodium salt was 
added post-transfection for 48 h, prior to harvesting the cells (performed in 
collaboration with Ms Fiona Fraser). Figure 3.2A revealed strong expression of 
zymogens representing full-length ADAMTS15 (ADAMTS15-I), ADAMTS15-II, 
and -III deletion mutants in the CL (top panel). In the CM, levels of both zymogen 
and mature ADAMTS15-I, ADAMTS15-II, and ADAMTS15-III protein was 
enhanced by the addition of heparin (Figure 3.2A, middle panel). ADAMTS5 was 
used as a positive control (data not shown) as it had been previously reported to be 
heparin-sensitive (13). These data suggested a strong association of ADAMTS15 
with the ECM via putative heparin-binding sites. The GAPDH loading controls are 
shown for the CM (Figure 3.2A, bottom panel). In additional experiments, heparin 
sensitivity was not as apparent for the ADAMTS15-IV deletion mutant (data not 
shown). It was therefore concluded that the spacer domain of ADAMTS15 could 
mediate heparin binding but could not rule out the possibility that domains C-
terminal to the spacer domain also possess heparin-binding properties.  
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Figure 3.1. ADAMTS15 constructs and their expression 
(A) Schematic diagram of full-length (I) and truncated (II-VII) forms of ADAMTS15. Functional 
domains and motifs are shown, with relevant amino acids numbered. The furin cleavage site present 
in the pro-domain is represented with an arrow, and the C-terminal Myc/His tag indicated. (B) 
Expression of full-length ADAMTS15 (ADAMTS15-I) and its domain deletion constructs 
(ADAMTS15-II through VII) in COS-7 cell lysate (CL) (top panel) and the corresponding 
conditioned media (CM) (third panel - asterisks indicate mature forms of ADAMTS15) detected by 
Western blot analysis using anti-Myc. GAPDH was used as a loading control in both CL (second 
panel) and CM (bottom panel). Only the mature form of ADAMTS15-VI was detected in the CL. 
Note the increasingly poor detection of ADAMTS15-I through IV in the CM. Similar results were 
obtained in transfected HEK293T cells. Z, zymogen; M, mature; U, untransfected. 
 
 
 
 56 
 
 
Figure 3.2. ADAMTS15 levels in the culture medium are enhanced by the addition of heparin 
(A) Expression of full-length ADAMTS15 (ADAMTS15-I), and deletion constructs ADAMTS15-
II and ADAMTS15-III in cell lysate (CL) (top panel) and the corresponding conditioned media 
(CM) (middle panel) ± heparin sodium salt treatment detected using the anti-Myc antibody. GAPDH 
was used as a loading control in CM (bottom panel). Note the enhanced levels of each form of 
ADAMTS15 in CM with the addition of heparin. (B) Expression of ADAMTS15-III (positive 
control) and ADAMTS15 ProCat (ADAMTS15-VII) in CM ± heparin sodium salt treatment 
detected using the anti-Myc antibody (top panel). GAPDH was used as a loading control in CM 
(bottom panel). A small but consistent enhancement in detection of ProCat was seen in CM upon 
heparin treatment. (C) Expression of ADAMTS15-III (positive control) and ADAMTS15 ProCat 
(ADAMTS15-VII) in CL (top panel) corresponding to the CM shown in B, detected with the anti-
Myc antibody. GAPDH was used as a loading control in CL (bottom panel). Z, zymogen; M, mature; 
U, untransfected. 
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To determine whether ADAMTS15 ProCat (ADAMTS15-VII) was also heparin-
sensitive, the experiment was repeated with the ADAMTS15 ProCat construct 
using ADAMTS15-III as a positive control. Heparin enhanced the detection of both 
the zymogen and mature forms of ADAMTS15 ProCat (ADAMTS15-VII) in the 
CM (Figure 3.2B, top panel), indicating that the catalytic domain of ADAMTS15 
could also possess ECM-binding properties. ADAMTS15 ProCat zymogen levels 
in the corresponding CL were similar between treatments (Figure 3.2C, top panel). 
GAPDH was used as a loading control for CM (Figure 3.2B, bottom panel) and CL 
(Figure 3.2C, bottom panel). 
3.2 ADAMTS15 Is Cell-surface Localised 
To determine whether ADAMTS15 was localised to the cell surface, transfected 
cells were subjected to cell surface biotinylation as described previously for the 
related proteoglycanase ADAMTS9 (5). Both full-length (ADAMTS15-I) and 
ProCat (ADAMTS15-VII) zymogens were present on the cell surface, along with 
the ADAMTS9 ProCat zymogen, which was used as a positive control (Figure 
3.3A, asterisks) (245). Robust levels of each zymogen were detected in the 
corresponding CL (Figure 3.3B, top panel), with GAPDH used as a proxy readout 
of cellular input (Figure 3.3B, bottom panel). Next, confocal microscopy was 
utilised to reveal the extent to which ADAMTS15 was localised to the cell surface. 
Constructs encoding both full-length (ADAMTS15-I) and ProCat (ADAMTS15-
VII) were transfected into COS-7 cells and immunocytochemistry was performed 
on non-permeabilised cells with the anti-Myc antibody to detect ADAMTS15 
protein and phalloidin to stain the cell cytoskeleton (258). Both full-length 
(ADAMTS15-I) and ProCat (ADAMTS15-VII) showed punctate staining 
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characteristic of cell-surface localisation similarly shown for the cell-surface 
localised ADAMTS-like protein Punctin (ADAMTSL1) (258) (Figure 3.3C). 
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Figure 3.3. ADAMTS15 is localised to the cell surface 
(A) Detection of full-length ADAMTS15 (ADAMTS15-I), and ProCat (ADAMTS15-VII) on the 
cell surface (asterisks) with minimal to no detection in the case of trypsin-treated cells. (B) Levels 
of zymogens detected in cell lysates (CL) after cell-surface biotinylation (top panel) and 
corresponding levels of GAPDH (bottom panel). Z, zymogen; 9-PC, ADAMTS9 ProCat; U, 
untransfected. (C) Confocal immunofluorescence microscopy of COS-7 cells expressing full-length 
(ADAMTS15-I) and ProCat (ADAMTS15-VII), detected using the anti-Myc antibody (green) with 
Phalloidin (red). Note the punctate expression on the cell surface (arrows). Inset containing no 
primary antibody control (c). Nuclei stained with DAPI are blue. Scale bar = 50 μm.  
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3.3 ADAMTS15 Propeptide Is Cleaved by Furin at Position 
RAKR212 
Because the ADAMTS15 ProCat (ADAMTS15-VII) construct was robustly 
expressed and processed, this construct was used to determine the mechanism of 
ADAMTS15 propeptide processing in a similar manner to that previously 
described for ADAMTS5 and ADAMTS9 (13, 245). Cell lines expressing 
ADAMTS15 ProCat were treated with the furin-specific inhibitor dec-RVKR-cmk 
(performed by Ms Fiona Fraser). The addition of 50 μM dec-RVKR-cmk to 
transfected cells had no effect on zymogen levels in CL samples (Figure 3.4A, top 
panel) but significantly enhanced detection of the Myc-tagged zymogen in the CM 
(Figure 3.4A, third panel, white box) and reduced the levels of the mature form 
accordingly, indicating that furin activity was necessary for ADAMTS15 
propeptide cleavage. GAPDH was used as a loading control for CL (Figure 3.4A, 
second panel) and CM (Figure 3.4A, bottom panel). Next, the P1 arginine residue 
of the predicted furin cleavage site RAKR212↓ was mutated to an alanine (R212A) 
(performed by Dr Daniel McCulloch) in the ADAMTS15-VII construct and 
expressed it in HEK293T or COS-7 cells (performed by Ms Fiona Fraser). Similar 
to the treatment with dec-RVKR-cmk, the R212A mutation led to a reduction of 
propeptide cleavage in the CM (Figure 3.4B, third panel) with no effect on levels 
of zymogens in the CL (Figure 3.4B, top panel). GAPDH was used as a loading 
control in CL (Figure 3.4B, second panel) and CM (Figure 3.4B, bottom panel). 
Similar results were seen in CM using the anti-ADAMTS15 propeptide antibody 
(Figure 3.4C, top panel) confirming that RAKR212↓ is a major furin cleavage site 
for ADAMTS15 propeptide processing. GAPDH was used as a loading control in 
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CM (Figure 3.4C, bottom panel). To confirm full-length ADAMTS15 was similarly 
processed, the same R212A mutation was introduced into the ADAMTS15-I 
construct and observed that propeptide processing was also reduced compared with 
either wild-type or catalytically-inactive (E362A) ADAMTS15 in CM (Figure 
3.4D, top panel, asterisk) (performed by Ms Fiona Fraser). However, the effect was 
less prominent, possibly due to the poorer levels of detection of full-length 
ADAMTS15 as compared with its ProCat counterpart. Similar levels of zymogens 
were seen in the corresponding CL (Figure 3.4D, third panel). GAPDH was used 
as a loading control in CM (Figure 3.4D, second panel) and CL (Figure 3.4D, 
bottom panel). 
3.4 Pro-domain of ADAMTS15 Is N-Glycosylated 
Next, the extent of N-glycosylation of ADAMTS15 was determined since it 
contains four predicted N-glycosylation sites (Uni-ProtKB/Swiss-Prot accession 
number P59384) (Figure 3.1A). Treatment of full-length ADAMTS15 expressed in 
COS-7 cells with PNGaseF produced a reproducible increase in its electrophoretic 
mobility (Figure 3.5A) indicating the presence of N-linked glycosylation. When 
COS-7-expressed ADAMTS15 ProCat protein was treated with PNGaseF, the 
zymogen doublet seen in other experiments (for example Figure 3.4, A and B, top 
panels) disappeared, and enhanced detection of the lower molecular weight species 
was observed (Figure 3.5B). Site-directed mutagenesis of the putative N-
glycosylation site in the ProCat construct (N141Q) generated a band of equivalent 
electrophoretic mobilities to the lower band (Figure 3.5C). Treatment of N141Q 
ProCat with PNGaseF had no effect on its electrophoretic mobility (Figure 3.5D). 
Thus, the predicted N-glycosylation site on the pro-domain of ADAMTS15 (Figure 
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3.1A) is modified by N-linked glycans in this expression system. Notably, the N-
glycan deficient ADAMTS15 ProCat zymogen was effectively secreted from the 
cell into the CM (Figure 3.5E, top panel), unlike the ADAMTS9 ProCat, which 
required N-glycosylation for effective secretion (16) (performed by Ms Fiona 
Fraser). GAPDH was used as a loading control in CM (Figure 3.5E, bottom panel). 
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Figure 3.4. ADAMTS15 propeptide processing 
(A) Expression of ADAMTS15 ProCat (ADAMTS15-VII) treated ± furin inhibitor dec-RVKR-cmk 
in COS-7 cell lysate (CL) (top panel) and conditioned media (CM) (third panel) using the anti-Myc 
antibody. GAPDH was used as a loading control in both CL (second panel) and CM (bottom panel). 
Note the enhanced detection of the zymogen in the CM upon treatment with the furin inhibitor (third 
panel, white box) and corresponding decrease in expression of the mature form. DMSO, vehicle 
control. (B) Expression of ADAMTS15 ProCat (ADAMTS15-VII) and its corresponding R212A 
mutant in COS-7 CL (top panel) and CM (third panel) using the anti-Myc antibody. GAPDH was 
used as a loading control in both CL (second panel) and CM (bottom panel). Note the enhanced 
detection of the R212A mutant zymogen in the CM (third panel) and corresponding decrease in 
expression of the mature form. (C) Expression of ADAMTS15 ProCat (ADAMTS15-VII) and its 
corresponding R212A mutant in COS-7 CM (top panel) detected with the anti-ADAMTS15 
propeptide antibody. GAPDH was used as a loading control in the CM (bottom panel). Note the 
enhanced detection of the R212A mutant zymogen in the CM and corresponding decrease in 
detection of the pro-domain. Pro, pro-domain. (D) Expression of full-length ADAMTS15 
(ADAMTS15-I) wild-type, E362A and R212A in the CM of transfected COS-7 cells (top panel). 
Similar levels of zymogens were observed in the corresponding CL (third panel). GAPDH was used 
as a loading control in both CM (second panel) and CL (bottom panel). Z, zymogen; M, mature; U, 
untransfected; WT, wild-type. 
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Figure 3.5. ADAMTS15 is modified by N-linked glycans 
(A-B) Expression of full-length ADAMTS15 (ADAMTS15-I) and ProCat ADAMTS15 
(ADAMTS15-VII) respectively, in transfected COS-7 cell lysate (CL) subsequently treated with 
PNGaseF and detected using the anti-Myc antibody. Note the ProCat doublet in panel B reduced to 
singlet species upon treatment with PNGaseF. (C) Expression of ADAMTS15 ProCat 
(ADAMTS15-VII) N141Q in COS-7 cells results in a similar shift in electrophoretic mobility as 
shown in B. (D) Treatment of recombinant wild-type or N141Q ADAMTS15 ProCat (ADAMTS15-
VII) with PNGaseF. Note that no further electrophoretic mobility shift was observed in the N141Q 
recombinant ADAMTS15 ProCat (ADAMTS15-VII) protein when treated with PNGaseF. (E) 
Expression of wild-type or N141Q ADAMTS15 ProCat (ADAMTS15-VII) in COS-7 conditioned 
media (CM) (top panel). GAPDH was used as a loading control in CM (bottom panel). WT, wild-
type; Z, zymogen; M, mature; U, untransfected. 
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3.5 ADAMTS15 Cleaves V1 Versican at E441A to Generate the 
G1-DPEAAE Neoepitope 
Since ADAMTS15 is phylogenetically related to the proteoglycanase clade of 
ADAMTS enzymes, it was important to determine whether it too had proteolytic 
activity toward versican (V1) (Figure 3.6A), as described previously for several 
other ADAMTS proteoglycanases. Using recombinant V1 versican-enriched CM 
(Figure 3.6B) in a well-established assay (13, 16, 34, 243), full-length 
ADAMTS15-I (Figure 3.6C) showed robust versicanase activity after a 16 h 
incubation (performed by Mr Adam Smith). The addition of dec-RVKR-cmk 
during its biosynthesis, prior to adding the V1 versican substrate, reduced full-
length V1 versicanase activity to background levels (Figure 3.6C), demonstrating 
that pro-domain removal is necessary for catalytic activation and substrate cleavage 
by ADAMTS15. All forms of ADAMTS15 cleaved V1 versican at the predicted 
E441↓442A cleavage site, generating the immunoreactive DPEAAE neoepitope 
(versikine; data not shown) As a control for catalytic activity, an active-site mutant 
E362A of full-length ADAMTS15 was generated, which only showed background 
levels of catalytic activity towards V1 versican in the same assay (data not shown). 
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Figure 3.6. ADAMTS15 cleaves versican at E441A generating the G1-DPEAAE neoepitope 
(A) Schematic representation of V1 versican cleavage by ADAMTS15 generating the DPEAAE 
neoepitope (versikine). (B) Expression of V1 versican in conditioned media (CM) of HEK293T 
cells (open bracket and arrow). C’ABC, chondroitinase ABC; CL, cell lysate. (C) Detection of the 
DPEAAE neoepitope generated by full-length (FL (I)) ADAMTS15 (ADAMTS15-I) after 
biosynthesis ± dec-RVKR-cmk and subsequent incubation with recombinant V1 versican enriched 
conditioned medium represented in panel B. DMSO, vehicle control; U, untransfected. 
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3.6 Adamts15 Expression Overlaps with Other ADAMTS 
Proteoglycanases and Versican in Key Developmental Time 
Points during Murine Embryogenesis and Is Highly Expressed in 
the Mouse Colon 
Using in situ hybridisation (performed by Dr Daniel McCulloch), alongside 
immunofluorescence (performed in collaboration with Ms Fiona Fraser) with the 
ADAMTS15 anti-propeptide antibody used in Figure 3.4C, key sites of expression 
of Adamts15 during mouse embryogenesis and in the adult colon were further 
defined. Early in development (E10.5 dpc), Adamts15 mRNA was strongly and 
specifically expressed in the developing heart tubes (Figure 3.7A, top panels). By 
E13.5 dpc, it became widely expressed in sites overlapping with those reported for 
other members of the ADAMTS proteoglycanases, including the perichondrium in 
the developing autopod, the brain, ear, whisker follicles, the vertebral column, and 
the epidermis (Figure 3.7A, middle and bottom panels). The same structures are 
shown in serial sections as staining positive for Adamts15 in a C57/Bl6 E14.5 dpc 
embryo on www.genepaint.org (Set ID: EB1749). Immunostaining showed 
ADAMTS15 localisation to the myocardium of the developing right atrium, the 
bulbous cordis (part of the future right ventricle) and in the airway epithelia of the 
main bronchiole in the lung bud at E11.5 dpc (Figure 3.7B, top panel), the vertebral 
column and dorsal root ganglia at E14.5 dpc (Figure 3.7B, second panel), and 
several sites in the developing hind limb, including the epidermis, joint capsule, 
patella, and patella-associated tendons and cartilage condensations of developing 
synovial joints and developing skeletal muscle at E15.5 (Figure 3.7B, third, fourth, 
and bottom panels). ADAMTS15 and hyaluronan co-localised in several structures 
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within E15.5 developing hind limbs, notably surrounding chondrocytes (Figure 
3.7C, top panel), within developing skeletal muscle and loose mesenchyme (Figure 
3.7C, second and third panels, respectively), and in the epidermis (Figure 3.7C, 
fourth panel). In the adult mouse colon, ADAMTS15 was highly expressed in the 
muscularis externa (inner circular smooth muscle and outer longitudinal smooth 
muscle), muscularis mucosa, submucosal glands, crypt, and villi epithelial cells, 
goblet cells, and lamina propria (Figure 3.7D). Pre-absorption with the 
immunogenic peptide greatly reduced the signal to background levels (Figure 3.7D, 
bottom right-hand panel) indicating the ADAMTS15 antibody was specific to its 
corresponding ADAMTS15 peptide epitope. 
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Figure 3.7. Expression of mouse ADAMTS15 during embryogenesis and in the adult colon 
(A) Whole-mount in situ hybridisation of Adamts15 in E10.5 (top panels) and E13.5 dpc mouse 
embryos (middle and bottom panels). Asterisk, ear; B, brain; Ep, epidermis; H, heart; PC, 
perichondrium; VB, vertebrae; Wf,  whisker follicles. Similar results were seen with two probes 
targeted to Adamts15 mRNA. (B) Immunohistochemistry using the anti-ADAMTS15 propeptide 
antibody in sections from E11.5, E14.5 and E15.5 dpc mouse embryos. For E11.5: BC, bulbous 
cordis; RA, right atrium; mc, myocardium; LB, lung bud; mb, main bronchiole; ae, airway epithelia. 
For E14.5: DRG, dorsal root ganglia; VB, vertebrae; si, segmental interzone. For E15.5: Ep, 
epidermis; D, dermis; SC, subcutus; jc, joint capsule; P, cartilage primordium of patella; lpt,  
ligamentum patellae; qft, quadriceps femoris tendon; white inset: ct, cartilage condensations; ch, 
chondrocytes; SJ, synovial joint; Skm, skeletal muscle. Scale bars = 50 μm except where indicated. 
(C) Immunohistochemistry using the anti-ADAMTS15 propeptide antibody (red) and biotinylated 
hyaluronan binding protein (bHABP) (green) in sections from E15.5 dpc mouse embryos. Co-
localisation (arrows), yellow. ct, cartilage condensations; ch, chondrocytes; Skm, skeletal muscle; 
PC, perichondrium; M, mesenchyme D, dermis Ep, epidermis. NP, no primary antibody control. 
Scale bars = 50 μm. (D) Immunohistochemistry using the anti-ADAMTS15 propeptide antibody in 
sections from an adult mouse intestine. ME, muscularis externa; V, villi; SM, submucosa; GC, 
goblet cell; C, crypts; CL, crypt lumen; CE, crypt epithelia; E, epithelium of villi; LP, lamina 
propria; MM, muscularis mucosa; ICSM, inner circular smooth muscle; OLSM, outer longitudinal 
smooth muscle. NP, no ADAMTS15 primary antibody; BP, blocking peptide (pre-absorption 
control). Scale bars = 50 μm. For B, C and D, DAPI stained nuclei are blue. 
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3.7 Discussion 
ADAMTS15 has recently taken the spotlight as a putative tumour suppressor gene 
in breast and colon cancer (88, 89). In addition, along with versican, it is also 
dysregulated in prostate cancer (55, 259, 260). However, the biology of 
ADAMTS15 is poorly described. As a highly conserved member of the 
proteoglycanase family, ADAMTS15 represents a putative versicanase. In this 
Chapter, the biosynthesis of ADAMTS15 has been characterised, its mechanism of 
activation and extracellular localisation determined and its activity towards V1 
versican confirmed. Its expression in key structures of the developing mouse 
embryo and the adult mouse colon have also been delineated. 
The ADAMTS15 zymogen was processed extracellularly, similar to ADAMTS5 
and ADAMTS9 (13, 245), and in contrast to ADAMTS1 and ADAMTS4, which 
are both activated intracellularly (19, 22, 261). The mechanism protecting 
intracellular propeptide processing of a select subset of the ADAMTS 
proteoglycanases is currently unknown. However, knowing their site(s) of 
activation is important when designing therapeutic inhibitors. For example, 
ADAMTS5, a major drug target in arthritis, is activated extracellularly, making 
itself and its activators - furin, PC7 and PACE4 (13, 14) appealing targets for drugs 
that do not cross the cell membrane. The involvement of ADAMTS15 activity in 
arthritis is not yet explored, although its mRNA is present and regulated in a similar 
manner to that of ADAMTS5 in osteoarthritis (262) and aggrecan has been 
previously reported as its substrate ((61, 62) and reviewed in (10)). Common to all 
ADAMTS proteoglycanases described to date is their propeptide processing by 
furin activity and their ability to cleave the versican VI splice variant at the 
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E441↓442A site generating the versikine neoepitope. The results in this Chapter show 
that ADAMTS15 is no exception. An interesting finding in this study, however, 
was the ability of the catalytic domain of ADAMTS15 alone to also cleave versican. 
This suggests that sites on the ADAMTS15 catalytic domain can mediate substrate 
binding as also indicated by its heparin sensitivity. This is in contrast to other 
ADAMTS proteoglycanases described to date, for example, ADAMTS5 ProCat 
activity against aggrecan (263). Although apparent autocatalysis in this Chapter 
using an E362A mutant was not observed (data not shown), other ADAMTS 
proteoglycanases have been reported to undergo this process (264) and the 
difficulty in detecting the mature form of full-length ADAMTS15 in this Chapter 
suggests it to be relatively unstable. The implication of C-terminal processing is the 
removal of substrate-binding sites found in the ancillary domain (263-265), 
essentially inactivating the protease. 
Substrate-binding sites in ADAMTS ancillary domains (exosites) have become 
regions of interest because competitive inhibitors could theoretically be designed 
against those sites. Therefore, determining their role in ECM binding is important. 
In this investigation, full-length active ADAMTS15 could not be detected 
efficiently in the conditioned medium without the addition of heparin. Thus, it is 
possible that full-length ADAMTS15 is tightly bound to the cell surface and ECM, 
as further confirmed in this study by in vitro cell-surface biotinylation, and co-
localisation with hyaluronan within tissues including skeletal muscle in the 
developing mouse hind limb, via specific ECM binding sites yet to be identified. 
Of the ADAMTS proteoglycanases, ADAMTS1, 4 and 9 are known to be localised 
to the cell surface (15, 18, 245), in contrast to ADAMTS5, which is present in the 
pericellular matrix but not found on the cell surface (13, 173). 
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Since nothing was known about the expression of Adamts15 during embryonic 
development, its expression across key developmental time-points that have been 
well described for other Adamts proteoglycanases and their substrate versican were 
characterised. Adamts15 was expressed in sites overlapping with versican, 
particularly during early heart development. Versican knockout mice (hdf) died of 
a heart defect at E10.5 dpc (64), while Adamts5 knockout mice and Adamts9 
heterozygote mice hearts presented with myxomatous heart valves and 
chondrogenic nodules respectively (66, 77). Given the strong and specific 
expression of Adamts15 in the E10.5 dpc mouse embryonic heart, it is attractive to 
hypothesise a role for ADAMTS15 during heart development through versican 
processing. Later in development, at E13.5 dpc, Adamts15 was expressed in the 
perichondrium of the developing autopod, where Adamts1, 5, 9 and 20 and versican 
(Cspg2) are all expressed and cooperate to stimulate interdigital apoptosis to form 
penatameric digits (34, 157, 266). Therefore, Adamts15 might also participate in 
this process. Interestingly, Adamts15 was also widely expressed in the hind limb of 
E15.5 embryos, including condensing cartilage of the long bones, a site overlapping 
with Adamts9 expression (157). At this stage of development, versican provides a 
transitional matrix that is cleared upon aggrecan deposition to form immature 
cartilage (267). A role for the ADAMTS proteoglycanases during this process has 
not yet been clearly defined, but both ADAMTS9 and ADAMTS15 are likely 
candidates. 
In this Chapter, ADAMTS15 expression was also shown in skeletal muscle of the 
developing mouse hind limb and in the skeletal muscle of the adult mouse. This is 
in accordance with the recent study showing ADAMTS15 could rescue an Adamts5 
deficient myoblast fusion defect using an in vitro model of skeletal muscle fibre 
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formation, mouse C2C12 cells (75). This study highlighted the expansion of a 
versican and hyaluronan-rich pericellular matrix surrounding myoblasts upon 
Adamts5 silencing, leading to the hypothesis that ADAMTS15 cooperates with 
ADAMTS5 to clear the pericellular matrix surrounding myoblasts during in vivo 
myogenesis, thus facilitating myoblast fusion and mature skeletal muscle fibre 
formation. 
Given the association between ADAMTS15 and colorectal cancer described above, 
it was investigated whether Adamts15 was expressed in the adult mouse colon. 
Immunostaining with an ADAMTS15 antibody directed towards its pro-domain 
robustly detected ADAMTS15 in several areas of the large intestine, including the 
muscular externa, submucosa and submucosal glands, crypts and villi. The function 
of ADAMTS15 in the colon is not known; however, its broad and high expression 
level in the large intestine is concordant with its proposed role in colorectal cancer 
as a tumour suppressor gene. Although the mechanism(s) underlying the tumour-
suppression capabilities of ADAMTS15 are yet to be determined, the anti-
angiogenic nature of several other ADAMTS proteoglycanases have been 
characterised, including ADAMTS15’s evolutionary partner ADAMTS8 (86, 268-
270). In addition, ADAMTS9 has recently been identified as a putative tumour-
suppressor gene through its anti-angiogenic properties in esophageal and 
nasalpharyngomal carcinoma (91). 
This Chapter highlights the similarities and differences in the activation, substrate 
specificity and expression of ADAMTS15 compared with other ADAMTS 
proteoglycanase family members. ADAMTS15 has been characterised as a novel 
versicanase that is present in biological tissues during embryogenesis relevant to 
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versican biology. These data provide a solid justification for further investigation 
of the function of ADAMTS15 during embryonic heart and musculoskeletal 
development, and gives further insights into its mechanism of action that might be 
relevant in pathologies such as arthritis and cancer.  
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4 The ADAMTS5 Metzincin Regulates Sonic 
Hedgehog Patterning during Zebrafish 
Gastrulation and Somitogenesis 
The results from this Chapter have been incorporated into a manuscript entitled: 
The ADAMTS5 Metzincin Regulates Sonic Hedgehog Patterning during 
Zebrafish Gastrulation and Somitogenesis by Carolyn M. Dancevic, Yann 
Gibert, Adam D. Smith, Nicole Stupka, Alister C. Ward and Daniel R. McCulloch 
which is in preparation.  
4.1 The Secreted Metalloproteinase adamts5 is Expressed in 
Zebrafish Embryos, and its Silencing Leads to a Moderate to 
Severely Distorted Posterior Trunk 
A role for ADAMTS5 during myoblast fusion in vitro has previously been 
demonstrated, with central nuclei observed in postnatal skeletal muscle from 
Adamts5-/- mice (75), which is highly suggestive of a developmental or skeletal 
muscle growth defect. To investigate this further, zebrafish have been used in this 
Chapter as a highly manipulable alternative model of vertebrate development. In a 
preliminary study, full-length adamts5 cDNA was cloned from zebrafish embryos 
and was shown to have tight conservation across vertebrates (41) (GenBank: 
JF778846.1) and adamts5 mRNA expression was observed during zebrafish 
embryogenesis (104). In line with previously published mouse expression data 
(74), adamts5 was also widely expressed in zebrafish adult organs (104). Since an 
adamts5 zebrafish mutant was not available at the onset of this investigation, a 
traditional approach to silence adamts5 was undertaken using two independent 
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morpholino antisense oligonucleotides (MOs) that were targeted to either the AUG 
translation start site (AUG-MO) or the splice site at the exon 2/3 boundary (2/3-
MO) (Figure 4.1A and B; Figure 4.1B by Mr Adam Smith), since exon 3 encodes 
for the catalytic domain of ADAMTS5 in human, mouse and zebrafish (41). 
Injection of either adamts5-MO resulted in a moderate to severe distortion of the 
posterior trunk in a significant number of embryos (Figure 4.1C; Figure by Mr 
Christopher Kintakas). The AUG-MO was subsequently used throughout the study 
since it gave a consistently stronger phenotype, although data is presented with the 
adamts5 2/3-MO (Figure 4.8). 
To obtain a detailed understanding of ADAMTS5 protein expression in zebrafish, 
whole-mount immunohistochemistry (IHC) was performed with a previously 
described anti-ADAMTS5 antibody directed to the pro-domain (13), which is 
highly conserved in ADAMTS5 across vertebrates (41). At ~80% epiboly (8 hours 
post fertilisation (hpf)), strong expression of ADAMTS5 was observed in the dorsal 
mesendoderm at the animal pole with variable expression ventrally at the vegetal 
pole (Figure 4.1D). At 18 and 24 hpf, after the commencement of somitogenesis, 
ADAMTS5 was expressed in the rostral neural tube (floor plate) and bilaterally in 
the prosencephalon (Figure 4.1D). Several attempts using multiple alternate in situ 
hybridisation probes that targeted adamts5 mRNA to elucidate its gene expression 
profile were unsuccessful (data not shown). However, ADAMTS5 protein 
expression was found to be specifically reduced upon adamts5 AUG-MO injection 
as shown by IHC and immunoblotting (Figure 4.1E), confirming the specificity of 
both the silencing approach used and of the anti-ADAMTS5 antibody against the 
corresponding zebrafish protein. 
 79 
 
 
 
 
 
 
 
 80 
 
Figure 4.1. Silencing of adamts5 expression in zebrafish embryos 
(A) Schematic representation of the adamts5 gene and mature mRNA and its targeting with 
antisense morpholino oligonucleotides (MOs) directed toward the start codon (AUG-MO) and exon 
2/3 splice site (2/3-MO), indicating the primers used for RT-PCR and the size of the resultant 
products. (B) RT-PCR of adamts5 from total isolated mRNA obtained from 24 hpf embryos 
following injection of the adamts5 2/3-MO at the 1-cell stage, showing amplicons a and b (asterisk) 
as depicted in panel A. β-actin was amplified in parallel as a house-keeping gene. (C) Distortion of 
the distal trunk (moderate and severe) observed at 24 hpf following MO silencing of adamts5. 
*P≤0.05, **P≤0.01. (D) ADAMTS5 expression in 8, 18 and 24 hpf wild-type embryos. Note strong 
expression in the dorsal mesoendoderm (8hpf - arrows) and variable expression ventrally (8 hpf - 
arrowhead), as well as expression in the neural floor-plate (18 and 24 hpf - arrows) and bilateral 
expression in the prosencephalon (24 hpf - arrowheads). Asterisks, no primary antibody control in 
the prosencephalon. (E) Left-hand panel - reduced ADAMTS5 expression seen in adamts5-MO 
injected embryos (asterisk) versus control (arrow). Right-hand panel - Western blot with the same 
anti-ADAMTS5 antibody showed reduced expression of the 120 kDa ADAMTS5 species (asterisk) 
in adamts5-MO injected embryos. C, Coomassie blue staining confirming even loading. All scale 
bars represent 50 μm. 
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4.2 TGF-β-dependent Shh Expression is Altered During Epiboly 
in adamts5 Morphant Embryos  
Sonic hedgehog (Shh) is an important morphogen that regulates CNS and skeletal 
muscle development. Since ADAMTS5 expression was observed at 80% epiboly, 
and in areas relevant to Shh patterning such as the neural floor-plate (Figure 4.1D), 
the potential for ADAMTS5 to regulate morphogen gradients was explored. The 
hypothesis was that expression of Shh was unlikely to be disrupted but rather its 
bioavailability and access to its receptor might be compromised due to the 
important role of ADAMTS5 in the regulation of ECM remodeling during 
development (34, 77, 271). The classic triangle shaped expression pattern of the 
sonic hedgehog gene (shh) at 8 hpf (Figure 4.2A - a-d) was elongated along either 
the left-right (L-R) or the anterior-posterior (A-P) axis in the majority of adamts5 
morphant embryos, with significantly more embryos being affected by the L-R 
patterning defect (P=0.007) or the A-P patterning defect (P=0.03) in the morphant 
group compared to the control group (Figure 4.2A - e-h). Means and standard 
deviations for this experiment are included in Appendix Table 1.1. Interestingly, 
the expression of the gene encoding the Shh receptor, Patched (ptch1), was largely 
unaffected in adamts5 morphants (Figure 4.2C).  
Next, to ensure the disrupted L-R and A-P phenotypes of shh were specific to the 
loss of ADAMTS5, mRNA encoding either full-length ADAMTS5 or the 
catalytically-inactive E411A mutant ADAMTS5 (13, 75) was co-injected with the 
adamts5 AUG-MO. Both forms of ADAMTS5 rescued both the L-R and A-P shh 
phenotypes to varying extents (Figure 4.2A - i-p and Figure 4.2B), suggesting a 
role for ADAMTS5 during epiboly that was independent of its catalytic activity. 
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Interestingly, the adamts5 morphants co-injected with E411A ADAMTS5 mRNA 
had significantly less embryos affected by the L-R patterning defect compared to 
adamts5 morphants (P=0.01) with this change less evident between the adamts5 
morphants and the adamts5 morphants co-injected with full-length ADAMTS5 
(P=0.20). Finally, co-injection of a p53-MO (272) along with the adamts5 AUG-
MO produced a similar phenotype to that of the adamts5 AUG-MO alone, with no 
significant difference in embryos affected by a L-R or A-P patterning defect 
(P=0.28), with the control group significantly different from both groups (P=0.04 
and P=0.004, adamts5 morphant and adamts5 morphants co-injected with p53-MO, 
respectively) (Figure 4.3A) confirming the phenotype was not due to induction of 
p53-mediated apoptosis. Means and standard deviations for this experiment are 
included in Appendix Table 1.1. 
Upon review of the literature, it was discovered that the phenotype observed in 
adamts5 morphants distinctly resembled that seen in skia/b morphants (273). The 
skia/b genes encode transcriptional activators of SMADs, which are downstream 
mediators of TGF-β and BMP signalling pathways, and key regulators of many 
developmental processes (274-276). Therefore, whole-mount 
immunohistochemistry was performed for pSMAD3 and pSMAD1/5/8 to 
determine whether TGF-β and/or BMP signalling, respectively, were affected in 
the adamts5 morphant embryos. Reduced pSMAD3 staining was observed in the 
dorsal mesoendoderm of 8 hpf adamts5 morphant embryos with aberrant 
expression apparent ventrally (Figure 4.4C - b), whilst pSMAD1/5/8 staining 
remained predominately ventral at the vegetal pole and was unperturbed (Figure 
4.5A).  
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Next, rescue of the altered shh expression in the adamts5 morphant embryos was 
attempted by activating endogenous TGF-β receptors using exogenous activated 
TGF-β. A dose-dependent rescue of the altered L-R and A-P staining was observed 
in adamts5 morphants treated with 50 or 100 pM TGF-β (Figure 4.4A - g-i and j-l, 
respectively, and Figure 4.4B). A significant decrease in embryos affected by the 
A-P patterning defect was observed in the 100 pM TGF-β-treated adamts5 
morphants compared to the adamts5 morphants (P=0.02). This occurred 
concurrently with increased pSMAD3 staining predominantly at the animal pole of 
adamts5 morphants (Figure 4.4C - c, c`) confirming the bioactivity of the added 
TGF-β. These data strongly suggested that reduced ADAMTS5 levels caused a 
decreased bioavailability of active TGF-β family signalling molecules within the 
extracellular environment during early embryogenesis, and that TGF-β family 
signalling molecules such as nodal and activin are able to regulate shh expression 
domains (Figure 4.4D). Means and standard deviations for this experiment are 
included in Appendix Table 1.1. To understand whether the effect was through the 
canonical TGF-β receptor pathway, rather than mediated via the BMP receptor, the 
same rescue experiment was attempted using recombinant BMP4. However, 
stimulation of BMP signalling had no effect on shh L-R or A-P patterning (Figure 
4.5B). 
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Figure 4.2. Silencing of adamts5 disrupts sonic hedgehog patterning 
(A) Expression of sonic hedgehog (shh) in 8 hpf embryos. Classic triangle-shaped expression pattern 
observed in embryos injected with control MO (a-d, arrows) with well-formed vertices (a-d, 
arrowheads). In contrast, adamts5 morphant embryos show disrupted shh patterning resulting in an 
anterior-posterior (A-P) elongation (e, open arrowheads) or left-right (L-R) loss of the triangular 
vertex (f, open arrowheads), as well as mild or unaffected shh patterning (g, arrow and arrowhead, 
h, arrow and asterisk = well-formed vertex). Rescue of A-P and L-R shh disruption in adamts5 
morphants co-injected with ADAMTS5 mRNA encoding wild-type ADAMTS5 (i-l, arrows and 
arrowheads) or E411A catalytically-inactive ADAMTS5 (m-p, arrows and arrowheads). (B) 
Quantitation of embryos showing normal or disrupted shh patterning as represented in panel A. (C) 
Sonic hedgehog receptor (Patched – ptch) staining in control (a, a`) and adamts5 morphants (b, b`). 
Arrows represent well-formed vertices, whereas asterisks demarcate narrow (a, b) or wide (a`, b`) 
base shown in both control and adamts5 morphant embryos. Scale bars represent 50 μm.  
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Figure 4.3. Quantitation of the effect of combinatorial microinjection of adamts5-MO and p53-
MO. 
Quantitation of control, adamts5-MO or adamts5-MO + p53-MO injected embryos showing normal 
or disrupted (L-R or A-P) patterning of shh (A) or myoD (B).  
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Figure 4.4. TGF-β signalling dependent shh patterning is disrupted in adamts5 morphant 
embryos 
(A) Expression of shh patterning in 8 hpf embryos. Classic triangle-shaped pattern observed in those 
injected with control MO (a-c, arrows) with well-formed vertices (a, arrowhead). In contrast, 
adamts5 morphant embryos show disrupted shh patterning resulting in an anterior-posterior (A-P) 
elongation (f, open arrowhead) or left-right (L-R) loss of the triangular vertices (d, open arrowhead), 
as well as mild or unaffected shh patterning (e). Rescue of A-P and L-R shh disruption in adamts5 
morphants treated with 50 pM TGF-β (g-i, arrows and arrowhead) or 100 pM TGF-β (j-l, arrows 
and arrowhead). (B) Quantitation of embryos showing normal or disrupted shh patterning as 
represented in panel A. (C) Dorsal mesoendodermal pSMAD3 staining in control (a, arrow) and 
adamts5 morphants (b, open arrowheads) or adamts5 morphants treated with 100 pM TGF-β (c, c`, 
arrowheads represent increased pSMAD3 staining in dorsal mesoendoderm, asterisks represent 
increased ventralised staining in the vegetal pole). (D) Working model showing adamts5 expression 
lies upstream of TGF-β signalling via pSMAD3 to determine shh patterning during epiboly. Scale 
bars represent 50 μm. 
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Figure 4.5. pSMAD1/5/8 staining and quantitation of BMP4 treatment 
(A) Detection of pSMAD 1/5/8 in ventral mesoendoderm of control embryos (a, arrow) and adamts5 
morphants (b, arrow) using immunofluorescence. V, ventral. (B) Quantitation of embryos showing 
normal or disrupted shh patterning in control, vehicle-treated, adamts5-MO, control + BMP4 or 
adamts5-MO + BMP4 treated embryos represented as percentages. Scale bar represents 50 μm. 
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4.3 Notochord Patterning is Perturbed in adamts5 Morphant 
Embryos  
Shh signalling from the notochord has been previously demonstrated to be 
important for adaxial and paraxial mesoderm formation and myod expression 
during myogenesis, a key marker of skeletal muscle development (277). Given the 
disruption of shh patterning during epiboly and the later distorted trunk of adamts5 
morphants, the possibility that shh expression could be disrupted later in 
development, at the onset of myogenesis, was also investigated in the adamts5 
morphants. Expression of both shh and no tail (ntl) (278) in axial mesoderm 
(notochord) remained similar between control and adamts5 morphant embryos at 
18 hpf (Figure 4.6A, B - shh and Figure 4.6C, D - ntl). However, the pattern of shh 
and ntl staining revealed convoluted notochordal patterning at 18 hpf (Figure 4.6A, 
B - shh and Figure 4.6C, D - ntl). 
4.4 Skeletal Muscle Formation is Disrupted in adamts5 Morphant 
Embryos 
The observed trunk distortion and disrupted notochordal patterning in the adamts5 
morphants collectively indicated that skeletal muscle might be affected, consistent 
with previous observations in Adamts5 knockout mice suggesting a skeletal muscle 
developmental defect (75). This led to a further examination of myod as well as the 
muscle fibres themselves using markers for actin. Firstly, disrupted patterning of 
myod was observed at 18 hpf in adamts5 morphants (Figure 4.6C and D), and 
secondly, severe disruption of F-actin filaments was revealed using phalloidin 
staining, including both irregularly spaced muscle fibres and muscle fibres that did 
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not span myotendinous junctions (Figure 4.6G - a and a`). In addition, U-shaped 
somites resembling a phenotype previously reported in shh mutant embryos (279) 
were also readily observed (Figure 4.6G - a`). Injection of adamts5 morpholino into 
transgenic Tg(acta1:mCherry)pc4 embryos expressing mCherry under the control of 
the skeletal muscle specific alpha-actin promoter (248) revealed similar disruptions 
in muscle fibre formation (Figure 4.6G - b and b`).  
The expression of myod in the adamts5 morphants was next examined at 12 hpf. 
Reduced or absent paraxial mesodermal myod expression was observed at this time 
point (Figure 4.7A - a, b), whereas expression of adaxial mesodermal myod was 
largely unaffected (Figure 4.7A - a, b). Similar observations were made upon co-
injection of the p53-MO with the adamts5 AUG-MO with no significant difference 
in embryos affected by absent paraxial staining between adamts5 morphants and 
adamts5 morphants co-injected with p53-MO (P=0.34) (Figure 4.3B) or with the 
adamts5 2/3-MO (Figure 4.8A and B). Again, to ensure that the specificity of the 
phenotype was due to reduced adamts5 expression, ADAMTS5 mRNA encoding 
either wild-type or catalytically-inactive (E411A) ADAMTS5 were co-injected, 
with both able to partially rescue the reduced paraxial mesodermal myod expression 
(Figure 4.7A - c and d, respectively, and Figure 4.7B). The absence of paraxial 
mesodermal myod expression further corroborated the previous observation that 
adamts5 morphants phenocopied ski a/b morphants (Fig. 4.2A - e-h). Means and 
standard deviations for this experiment are included in Appendix Table 1.1. 
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Figure 4.6. Notochord patterning and muscle fibre formation is perturbed in adamts5 
morphant embryos 
(A) Expression of shh in the notochord of 18 hpf control (a, a`, arrows) and adamts5 morphant (b, 
b`, open arrowheads) embryos, with medio-lateral deviation in the adamts5 morphants (b, b`). (B) 
Expression of ntl in the notochord of 18 hpf control (a, a`, arrows) and adamts5 morphant (b, b`, 
open arrowheads) embryos, with medio-lateral deviation in the adamts5 morphants. (C) Expression 
of myod in adaxial and paraxial mesoderm of 18 hpf control (a, a`) and adamts5 morphant (b, b`) 
embryos, with perturbed expression in the adamts5 morphants (open arrowheads). (D) Quantitation 
of embryos with perturbed myod expression in control and adamts5 morphant embryos demarcated 
in panel C. (E) Quantitation of affected notochords in control and adamts5 morphant embryos 
demarcated by shh in panel A. (F) Quantitation of affected notochords in control and adamts5 
morphant embryos demarcated by ntl in panel B. (G) Representative muscle fibre staining of 24 or 
48 hpf control and adamts5 morphant wild-type embryos stained with phalloidin (a and a` 
respectively) or Tg(acta1:mCherry)pc4 embryos imaged with fluorescence (278) (b and b`, 
respectively). U-shaped somites were prominent in adamts5 morphants (a` and b`, arrows) 
compared to the characteristic chevron patterning seen in control embryos (a and b, arrows), as well 
as muscle fibres that did not span the myotendinous junctions in adamts5 morphants (a` and b`, 
arrowheads) compared to control embryos (a and b, arrowheads). All scale bars represent 50 μm.  
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Figure 4.7. Loss of paraxial mesodermal myod expression in adamts5 morphant embryos 
(A) Expression of adaxial and paraxial myod in 12 hpf embryos injected with control embryos (a, 
arrowheads) and the loss of paraxial expression in adamts5 morphant embryos (b, ad denotes adaxial 
mesoderm), as well as mild or unaffected paraxial myod expression (b, open arrowheads). Rescue 
of paraxial myod expression in adamts5 morphants co-injected with mRNA encoding wild-type 
ADAMTS5 (c, arrows) or catalytically-inactive E411A ADAMTS5 (d, arrows). Control embryos 
injected with ADAMTS5 mRNA encoding wild-type ADAMTS5 showed unaffected myod 
expression in paraxial mesoderm (e, arrows). (B) Quantitation of presence or absence of myod 
patterning in embryos represented in panel A. Scale bars represent 50 μm. 
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Figure 4.8. Pattern of myod expression following adamts5 2/3-MO injection 
(A) Expression of myod in adaxial and paraxial mesoderm of 12 hpf control embryos (a, a`) and 
adamts5 morphants (b, b`), which is perturbed in the adamts5 morphants (b, b`, arrowheads). (B) 
Quantitation of embryos with perturbed myod expression in control and adamts5 morphant embryos 
represented in panel A. Scale bar represents 50 μm. 
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4.5 Receptor-Mediated Sonic Hedgehog Signalling is Dependent 
upon the Expression of ADAMTS5 
It was hypothesised that reduced ADAMTS5 could lead to an altered extracellular 
environment that might disrupt Shh signalling, and that since adaxial mesoderm is 
in closer proximity to the notochord it might be less disrupted compared to the 
paraxial mesoderm. Therefore, an experiment was designed using cyclopamine, an 
antagonist of the effector Smoothened (Smo) (280). This experiment aimed to 
understand whether Shh signalling through the Patched (Ptch) receptor, and 
therefore Smo, was impaired in the adamts5 morphants. The presence of 5 μM 
cyclopamine did not affect adaxial myod expression at 12 hpf in wild-type embryos 
(Figure 4.9A - g-i and B). However, treatment of adamts5 morphants with 5 μM 
cyclopamine severely affected adaxial expression of myod (Figure 4.9A - j-l and B) 
compared to untreated adamts5 morphant embryos, with significantly more 
adamts5 morphants treated with cyclopamine displaying an adaxial defect (P=0.05) 
(Figure 4.9A - d-f and B). This suggested a strong and specific interaction between 
adamts5 and Shh, such that they act synergistically to stimulate myod expression 
in adaxial mesoderm (Figure 4.10C). 
In a reciprocal experiment, a Smo agonist was used to confirm the dependency of 
Shh signalling on ADAMTS5 expression. The Smo agonist elicited a similar effect 
on adaxial myod expression on wild-type embryos to that observed in the adamts5 
morphants (Figure 4.10A - d-f and B), suggesting that stimulation of the Ptch 
receptor may result in a negative feedback loop, such as that previously identified 
in Drosophila (281). However, the same concentration of the Smo agonist rescued 
the loss of paraxial myod patterning in the adamts5 morphants, with significantly 
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less embryos in the Smo agonist-treated adamts5 morphants being affected by 
absent paraxial or adaxial staining compared to the adamts5 morphants (P=0.04) 
(Figure 4.10A - g-l and B). Means and standard deviations for this experiment are 
included in Appendix Table 1.1. Collectively, these data led to the conclusion that 
ADAMTS5 regulates Shh morphogen gradients during myogenesis, with 
ADAMTS5 necessary for Shh signalling through its receptor Ptch and activation of 
the effector Smo, but not for shh gene expression itself.  
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Figure 4.9. Synergistic regulation of myod expression by Shh and adamts5 
(A) Adaxial and paraxial myod expression in 12 hpf embryos treated with vehicle control (a-c arrows 
denote present paraxial myod expression in control embryos, with arrowhead representing some 
absent paraxial myod expression), vehicle + adamts5-MO (d-f, arrows represent absent paraxial 
myod expression in adamts5 morphants), 5 μM cyclopamine (g-i, arrowheads represent similar 
presence of paraxial myod staining compared to control group) and 5 μM cyclopamine + adamts5-
MO (j-l, open arrowheads represent absent adaxial myod expression not seen in any other group). 
(B) Quantitation of presence or absence of myod patterning in embryos represented in panel A. Scale 
bar represents 50 μm. 
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Figure 4.10. Synergistic regulation of myod expression by Shh and adamts5 
(A) Adaxial and paraxial myod expression in 12 hpf embryos treated with vehicle control (a-c 
arrows), 10 μM smoothened agonist (d-f, arrow, open arrowhead represents absent myod expression 
in paraxial mesoderm), vehicle + adamts5-MO (g-i, arrow, open arrowhead represents absent myod 
expression in paraxial mesoderm) and 10 μM smoothened agonist + adamts5-MO (j-l, arrow 
indicates myod expression present in paraxial mesoderm). (B) Quantitation of presence or absence 
of myod patterning in embryos represented in panel A. (C) Working model showing adamts5 and 
shh expression synergistically regulates Ptch receptor signalling and downstream activation of myod 
in adaxial and paraxial mesoderm. Expression of myod in adaxial and paraxial mesoderm in-turn 
regulate slow or fast muscle fate, respectively (277). Scale bar represents 50 μm. 
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4.6 Discussion 
The work described in this Chapter has identified two distinct stages of vertebrate 
development where Shh expression fields or activity are regulated by adamts5 gene 
expression. The altered shh expression pattern at 8 hpf in mesoendoderm and the 
altered or absent myod expression at 12 and 18 hpf in paraxial mesoderm observed 
in the adamts5 morphants represented phenocopies of skia/b morphants (273). The 
disrupted skeletal muscle fibre formation and U-shaped somites were also 
consistent with disrupted Shh signalling from the notochord and neural floor plate 
(277), where ADAMTS5 was shown to localise. These data suggest a mechanism 
by which ADAMTS5 regulates TGF-β signalling molecules such as nodal and 
activin during early development at the onset of gastrulation (80% epiboly in the 
zebrafish), and Shh signalling during myogenesis (Figures 4.2, 4.4 and 4.6, 
respectively). 
The altered phenotypes were rescued to varying extents in the adamts5 morphants 
not only with mRNA encoding active ADAMTS5, but also a catalytically-inactive 
ADAMTS5 mutant. Although unexpected, there is some precedence since 
ADAMTSL family members, which are essentially ADAMTS enzymes that lack 
an N-terminal propeptide and catalytic domain, have important functions (9). Most 
notably, mutations in the human ADAMTSL2 have been causally linked to the 
musculoskeletal disorder Geleophysic Dysplasia (6), where patients present with 
severe short stature, joint immobility and cardiac valvular abnormalities. 
Biochemically, ADAMTSL2 mediates fibrillin-2 microfibril assembly and 
ADAMTSL2 deficiency leads to aberrant TGF-β signalling (6). Given the gross 
morphology defects, disruption to muscle fibre formation, and altered TGF-β 
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signalling (pSMAD3) observed in the adamts5 morphants, a favourable hypothesis 
for results observed here is that microfibril assembly may also be disrupted in the 
adamts5 deficient embryos, which should be examined in further studies. 
Studies in the mouse limb bud showed reduced ADAMTS5 activity was associated 
with reduced BMP-mediated apoptosis, yet pSMAD1/5/8 signalling remained 
unperturbed. It was further shown that the generation of a bioactive ECM fragment 
of V0/V1 versican (versikine) (35, 282) was required for the sensitisation of cells 
to the action of BMPs (34). Although the research described here does not identify 
a substrate for zebrafish ADAMTS5, dermacan represents a substrate equivalent to 
V1 versican (106) and a good candidate for further investigation. Furthermore, a 
recent study suggested that sulphated proteoglycans, likely substrates for 
ADAMTS5, are co-receptors for Shh signalling (283). 
Altered TGF-β signaling was observed in developing heart valves of Adamts5 
deficient mice, with reduced SMAD2 signalling associated with irregular heart 
valve formation in those mice (77, 271). Altered TGF-β signalling was also 
observed during dermal wound repair in ADAMTS5 knockout mice (99), although 
in this context BMP signalling was also altered, unlike the scenario shown during 
zebrafish embryogenesis where BMP signalling - at least through its canonical 
pSMAD1/5/8 pathway - was unperturbed. In the zebrafish myotome, a complex 
interplay exists between BMP and fibroblast growth factor (FGF) signalling that 
determines slow muscle cell fate independent of Shh (284). Specific cell fields are 
fated towards slow-twitch muscle fibres or muscle pioneer cells depending upon 
the reduction of FGF signalling antagonism mediated by BMP activity within those 
fields. Such interplay hypothesises that Shh signalling and cell fate is regulated 
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independent of BMP signalling and gives credence to the observations reported 
here that TGF-β but not BMP signalling was important, at least during epiboly. 
ADAMTS5-Shh interactions have previously been observed in vertebrates. 
Pharmacological or genetic inhibition of Shh signalling in mice reduced the severity 
of osteoarthritis, with runt-related transcription factor-2 (RUNX-2) identified as a 
potential mediator of this process though regulation of Adamts5 expression (285). 
ADAMTS5 is a major drug target in arthritis since mice with an Adamts5 allele 
encoding for catalytically-inactive ADAMTS5 are protected from inflammatory 
arthritis and osteoarthritis (78, 79). In this context, aggrecan, the core proteoglycan 
of articular cartilage, is the ADAMTS5 substrate that is enzymatically degraded to 
compromise articular joint function. Although the aggrecan orthologue is present 
in zebrafish (106), it is unlikely to be involved in the phenotype observed in this 
current study as alcian blue staining showed no alterations in zebrafish cartilage 
elements in the adamts5 morphants (data not shown), and catalytically-inactive 
ADAMTS5 also rescued adamts5 morphant phenotypes.  
The results described in this Chapter have identified a role for adamts5, a gene 
encoding a secreted metzincin in one of the most important pathways determining 
cell and tissue fates during vertebrate development. This adds a crucial step in the 
understanding of Shh regulation in two important developmental contexts. These 
data have wide relevance to vertebrate biology, not only in the physiology of 
development but also in pathology, given the importance of ADAMTS5 in disease 
(10). Future work regarding the substrate specificity of ADAMTS5 in zebrafish is 
required to determine whether the interaction of ADAMTS5 with Shh and TGF-β 
pathways are partially or wholly independent of proteoglycanase activity. 
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5 The Effect of Statins and Current Therapeutics on 
Cartilage Release in the Synovial Fluid of Arthritis 
Patients: A Retrospective Study 
The results from this Chapter have been incorporated into a manuscript entitled: 
The Effect of Statins and Current Therapeutics on Cartilage Release in the 
Synovial Fluid of Arthritis Patients: A Retrospective Study by Carolyn M 
Dancevic, Tamsyn M Crowley, Gemma E Strickland, Hedley T Griffiths, Nigel C 
Wood and Daniel R McCulloch, which is currently under review.  
5.1 Overview 
Cleavage of the ADAMTS5 pro-domain from the catalytic domain (mature form) 
by proprotein convertases, such as furin and PACE-4, is essential for its enzymatic 
activity towards proteoglycans; for example, the cleavage of aggrecan in arthritis 
(13, 14, 176, 243). Statins are known to block the mevalonate synthesis pathway 
through inhibition of HMGCoA reductase activity, effectively inhibiting formation 
of several lipids such as dolichol and low density lipoproteins (LDL) (238-240, 
286). Dolichol pyrophosphate is the lipid in the N-glycosylation pathway that is 
linked to a precursor oligosaccharide prior to entry into the endoplasmic reticulum, 
where the addition of N-glycans to a specific amino acids in a protein occurs. Thus, 
statins prevent the inception of the N-glycosylation pathway, and may therefore 
inhibit this post-translational modification with respect to the proprotein 
convertases. It was, therefore, hypothesised that statin-mediated inhibition of the 
N-glycosylation of furin would consequently inhibit the cleavage of the ADAMTS5 
pro-domain. This may have significant implications for the treatment of arthritis, 
as a mechanism by which statins may impact on the etiology of arthritis.  
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5.2 Statins Prevent Cleavage of the ADAMTS5 Pro-Domain from 
the Catalytic Domain 
HEK293T cells were transfected with either ProCat (containing only the propeptide 
and catalytic domain) or full-length Adamts5 and incubated with 10 or 20 μM 
atorvastatin. Cell lysates and conditioned media were analysed by Western blot 
using anti-Myc (Figure 5.1, first and third panels) antibody as both forms of 
ADAMTS5 contain a Myc tag at their C-terminus, with GAPDH used as a loading 
control (Figure 5.1, second and fourth panel). Only 20 μM atorvastatin slightly 
decreased the amount of the mature form (white asterisk, 85 kDa) of full-length 
ADAMTS5, but increased the zymogen (red asterisk; 120 kDa) in the conditioned 
media (Figure 5.1, third panel). Decreased catalytic domain (mature form; white 
asterisk, 30 kDa) and increased ProCat ADAMTS5 (red asterisk, 55 kDa) in the 
conditioned media collected was also observed (Figure 5.1, third panel). No 
changes were observed in cell lysate (Figure 5.1, first panel) as expected since 
ADAMTS5 is an extracellularly activated proteinase. The increase in ProCat 
ADAMTS5 was only observed in the 10 μM treatment group, whereas a decrease 
in ProCat ADAMTS5 with a concurrent decrease in the mature form was observed 
in the 20 μM treatment group, indicative of an overall decrease in ADAMTS5 in 
the conditioned media (Figure 5.1, third panel). These data provide proof-of-
principle evidence that statins can inhibit the cleavage of the pro-domain of 
ADAMTS5 in vitro, preventing formation of the mature form, with increasing 
concentrations decreasing overall ADAMTS5 expression. This is likely to have the 
subsequent effect of inhibiting aggrecan cleavage.    
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5.3 Glycosaminoglycan Content of Patient Synovial Fluid 
5.3.1 Age 
To further analyse the effect of statins in arthritis, a pilot retrospective investigation 
was carried out in which the synovial fluid from arthritis patients was assessed 
using the dimethylmethylene blue (DMMB) assay to detect sulphated 
glycosaminoglycan (S-GAG) as a proxy marker of cartilage destruction. This 
allowed comparison of patients currently prescribed statins compared to other 
current arthritis therapies, with respect to protection against cartilage degradation. 
A chondroitin sulphate standard curve ranging between 0 and 60 μg/ml was used 
(Figure 5.2A) to standardise all samples and determine the amount of chondroitin 
sulphate (or other sulphated glycosaminoglycans such as keratan sulphate) in each 
sample. If the samples fell higher than the linear range of the standard curve they 
were diluted 1:2 (287, 288).  
Since age has been shown to correlate with changes in cartilage sulphation patterns 
and levels (289), the possibility that age was a confounding factor in the study was 
investigated. A total of 118 arthritis patients were analysed, who predominately had 
osteoarthritis (OA), rheumatoid arthritis (RA) and psoriatic arthritis (PSA), with a 
small cohort with inflammatory arthritis, juvenile idiopathic arthritis, gout and 
reactive arthritis. A low correlation for decreasing S-GAG (μg/ml) levels with age 
were observed, however the differences were not significantly different (Figure 
5.2B, P=0.50; R2=0.004). No significant differences were observed between senior 
(61+ years), middle (31-60 years) and young (18-30 years) age groups (n=53, n=53 
and n=13, respectively, P=0.19; Figure 5.2C). Therefore, age-adjusted rates were 
not required in subsequent statistical analyses.  
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Volume of synovial fluid obtained from each patient was analysed against S-GAG 
values to determine whether volume extracted influenced S-GAG levels (Figure 
5.2D). It was determined that there was little correlation between volume obtained 
and amount of S-GAG in the synovial fluid (P=0.92; R2=≤0.0001). Although some 
patient information was missing from the study, the gender of each patient was 
obtained for the majority of the cohort (females n=75; males n=39). It was 
established that there was no significant difference in S-GAG levels between males 
and females in this cohort (Figure 5.2E, P=0.34). 
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Figure 5.1. The effect of statin treatment on ADAMTS5 propeptide cleavage 
HEK293T cells were transfected with either ProCat or full-length ADAMTS5 and then treated with 
10 μM (+) or 20 μM (++) atorvastatin to determine whether ADAMTS5 propeptide cleavage was 
inhibited. Anti-Myc antibody (first and third panels) was used to detect these proteins in the cell 
lysate (CL) and conditioned media (CM), with anti-GAPDH used as the loading control (second 
and fourth panels). Red asterisks denote the zymogen or inactive form of ADAMTS5 (either ProCat 
or full-length) and white asterisks denote the mature form of ADAMTS5 (both full-length and 
ProCat forms lose the propeptide domain and the mature ProCat contains only the catalytic domain). 
An increase in ProCat (red asterisk; 55 kDa) and decrease in mature form (white asterisk; 30 kDa) 
was evident upon treatment with 10 μM atorvastatin with both forms decreased upon 20 μM 
treatment. An increase in the full-length zymogen (red asterisk; 120 kDa) was evident upon statin 
treatment, with the mature form (white asterisk; 85 kDa) slightly decreased.   
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Figure 5.2. Age association of cartilage release into the synovial fluid 
(A) An example of a chondroitin sulphate standard curve (ranging between 0-60 μg/ml) used to 
normalise all synovial fluid samples, with an R2 value of 0.98. (B) S-GAG levels (μg/ml) of patients 
by age (P=0.48) with a slight negative correlation observed (R2=0.004). (C) S-GAG levels in 
arthritis patients (predominately osteoarthritis [OA], rheumatoid arthritis [RA] and psoriatic arthritis 
[PSA]; n=118) grouped by age range: n=13, 18-29 years (young), n=53, 31-60 years (middle) and 
n=53, 61-92 (elderly) and S-GAG was measured with no significant difference observed between 
the groups (P=0.19). (D) S-GAG levels of arthritis patients according to volume of synovial fluid 
obtained (P=0.92) with little correlation observed (R2=≤0.001). (E) S-GAG levels according to 
gender (females n=75; males n=39) with no significant difference observed between the groups 
(P=0.34).  
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5.3.2 Osteoarthritis (OA) 
OA patients undertaking a NSAIDs treatment regimen had significantly increased 
levels of S-GAG compared to those not undertaking NSAID treatments (Figure 
5.3B; P=0.024), indicating OA patients on NSAIDs may have accelerated cartilage 
destruction. However, when patients on other drug regimens were discounted, 
statistical significance disappeared due to reduced power (P=0.39). In OA patients, 
the level of S-GAG in the synovial fluid of those undertaking a statin treatment 
regimen was reduced compared to those not undertaking statin treatments (Figure 
5.3A, P=0.03), indicative of a potential protective effect of statins on cartilage 
degradation. When patients on combined regimens were discounted, this difference 
remained significant (P=0.05). OA patients taking aspirin for pain relief had no 
difference in S-GAG levels compared to those not taking aspirin (Figure 5.3C, 
P=0.59) suggesting an absence of a chondroprotective effect for aspirin.  
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Figure 5.3. Effect of statin, NSAID and aspirin therapies upon S-GAG release into the synovial 
fluid of OA patients 
(A) S-GAG (μg/ml) levels in OA patients undergoing a statin regimen compared to those not on 
statins. A significant difference was observed between the groups (*P=0.03; P=0.05 when 
combination treatment was discounted). (B) S-GAG in OA patients undertaking a NSAID treatment 
regimen compared to patients not taking NSAIDs. A significant difference was observed between 
the groups (°P=0.024; P=0.39 when combination treatment was discounted). (C) S-GAG levels in 
OA patients undertaking an aspirin treatment regimen compared to patients not taking aspirin. No 
significant difference in S-GAG levels was observed between the groups (P=0.59). 
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5.3.3 Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PSA) 
The “gold-standard” therapeutic agent for RA, MTX, has profound disease-
modifying properties (290-293). RA patients undertaking a MTX regimen showed 
no significant difference in S-GAG content in their synovial fluid compared to 
those not undertaking a MTX regimen (Figure 5.4A, P=0.63). Most RA patients 
were on combined regimens with more than one DMARD. Even when these 
patients were discounted statistical significance was not reached (P=0.29), 
suggesting that in our study, MTX alone may have a greater effect on decreasing 
S-GAG than MTX in combination with another DMARD, although not to a 
statistically significant extent. RA patients on a statin regimen had no significant 
difference in S-GAG compared to patients not undergoing a statin regimen (Figure 
5.4B; P=0.94). However, PSA patients that had also been prescribed a MTX 
treatment regimen had significantly increased levels of S-GAG in their synovial 
fluid compared to those not undertaking a MTX treatment (Figure 5.4C, P=0.018).  
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Figure 5.4. Effects of MTX therapy upon S-GAG release in PSA and RA patients 
(A) S-GAG (μg/ml) levels of RA patients undergoing MTX treatment compared to patients not 
taking MTX. No significant difference between the groups was observed (P=0.63; P=0.29 when 
combination treatment was discounted). (B) S-GAG levels of RA patients taking statins compared 
to those not taking statins. No significant difference between the groups was observed (P=94). (C) 
S-GAG levels of PSA patients taking MTX compared to patients not taking MTX. A significant 
difference between the groups was observed (*P=0.018).   
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Arthritis Treatment Number of 
Samples 
Mean S-GAG 
(μg/ml) 
OA Non-Statin 26 14.70 
OA Statin 16 9.33 
OA No Treatment 20 12.84 
OA Statin Only 14 7.93 
OA Non-NSAIDs 35 11.42 
OA NSAIDs 8 20.31 
OA No Treatment 19 13.45 
OA NSAIDs Only 5 18.02 
OA Non-Aspirin 35 12.62 
OA Aspirin 8 15.03 
RA Non-MTX 6 19.33 
RA MTX 22 12.93 
RA No Treatment 5 19.57 
RA MTX Only 4 9.09 
RA Non-Statin 22 14.30 
RA Statin 7 17.30 
PSA Non-MTX 7 6.90 
PSA MTX 7 16.20 
 
Table 5.1. Number of samples and mean values for the DMMB assay 
Summary of the amount of samples (n) and mean values (μg/ml) for each of the treatment groups 
contained within each arthritis type completed in the DMMB assay.  
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5.4 Inflammatory Cytokine Content of Patient Synovial Fluid 
Cytokine levels were quantified in patient synovial fluid to determine which 
therapeutics had the greatest affect in lowering levels of specific mediators of 
inflammation, and to ascertain whether those levels corresponded to the quantity of 
S-GAG determined in their respective synovial fluids. Since the predominant 
therapies in arthritis target the inflammatory cytokines IL-1α, IL-1β, IL-6 and TNF-
α, the levels of these cytokines were analysed.  
5.4.1 Osteoarthritis (OA) 
OA patients undertaking a NSAIDs regimen showed no differences in TNF-α levels 
compared to patients not on a NSAIDs regimen (Figure 5.5A, P=0.76). Synovial 
fluid levels of IL-6 were also not significantly different between NSAID (Figure 
5.6A) and non-NSAID treatment groups, although there was a trending increase in 
the NSAID group (P=0.12). Furthermore, there was no significant difference in IL-
1β between NSAID and non-NSAID treatment groups (Figure 5.7A, P=0.22). 
Moreover, IL-1α levels were not significantly different between the NSAID and 
non-NSAID groups (Figure 5.8A, P=0.45).   
TNF-α levels were not significantly different between patients undertaking statin 
treatments and not undertaking statin treatments (Figure 5.5B, P=0.54). OA 
patients undertaking a statin regimen compared to those not taking statins had no 
significant difference in levels of IL-6 (Figure 5.6B, P=0.83). Although no 
significance differences were observed in IL-1β levels between patients 
undertaking statin treatments and not undertaking statin treatment, a trend for lower 
levels in the statin group was apparent (Figure 5.7B, P=0.14). No significant 
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differences in OA patients IL-1α levels were demonstrated between statin and non-
statin treatment groups (Figure 5.8B, P=0.51). 
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Figure 5.5. Human TNF-α cytokine levels in the synovial fluid of patients 
(A) TNF-α levels (pg/ml) were analysed between the OA patients taking NSAIDs and the patients 
not taking NSAIDs. No significant difference was observed between the groups (P=0.63). (B) TNF-
α levels between OA patients taking statins compared to patients not taking statins. No significant 
difference between the groups was observed (P=0.34). (C-D) TNF-α levels of RA patients (C) and 
PSA (D) patients taking MTX compared to patients not taking MTX. No significant differences 
were observed between the groups (C, P=0.81; D, P=1.0). 
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Figure 5.6. Human IL-6 cytokine levels in the synovial fluid of patients 
(A) IL-6 (pg/ml) levels in OA patients taking NSAIDs compared to those not taking NSAIDs. No 
significant difference was observed between the groups (P=0.12). (B) IL-6 levels in OA patients 
taking statins compared to patients not taking statins. No significant difference was observed 
between the groups (P=0.78). (C) IL-6 levels in RA patients taking MTX compared to patients not 
taking MTX. No significant difference was observed between the groups (P=0.38). (D) IL-6 levels 
in PSA patients on either a MTX or non-MTX treatment regimen. No significant difference was 
observed between the groups (P=0.57).   
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5.4.2 Rheumatoid Arthritis (RA) 
In the case of RA patients, there were no significant differences in TNF-α levels 
between patients prescribed MTX versus patients not prescribed MTX (Figure 
5.5C, P=0.80). Similarly, IL-6 levels between the patients prescribed MTX and 
those not prescribed MTX were not significantly different (Figure 5.6C, P=0.38). 
IL-1β levels between patients prescribed MTX and those not prescribed MTX were 
also not significantly different (Figure 5.7C, P=1.0). However, there was a 
significant decrease in IL-1α levels in patients prescribed MTX versus patients not 
prescribed MTX (Figure 5.8C, P=0.04), suggesting this may be an underlying 
mechanism of action for the anti-inflammatory and immunosuppressive effects of 
MTX. 
5.4.3 Psoriatic Arthritis (PSA) 
In the case of PSA patients, there were no significant differences in TNF-α between 
patients prescribed MTX and those not prescribed MTX (Figure 5.5D, P=1.0). 
Furthermore, no significant differences were identified for IL-6 (Figure 5.6D, 
P=0.57), IL-1β (Figure 5.7D, P=1.0) and IL-1α (Figure 5.8D; P=0.39) between the 
patients prescribed MTX and those not prescribed MTX.   
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Figure 5.7. Human IL-1β cytokine levels in the synovial fluid of patients 
(A) IL-1β levels of OA patients taking NSAIDs compared to patients not taking NSAIDs. No 
significant difference was observed between the groups (P=0.31). (B) IL-1β levels of OA patients 
taking statins compared to those not taking statins. No significant difference was observed between 
the groups (P=0.14). (C) IL-1β levels of RA patients taking MTX compared to patients not taking 
MTX. No significant difference was observed between the groups (P=1.0). (D) IL-1β levels of PSA 
patients taking MTX compared to patients not taking MTX. No significant difference was observed 
between the groups (P=1.0).   
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Figure 5.8. Human IL-1α cytokine levels in the synovial fluid of patients 
(A) IL-1α levels of OA patients taking NSAIDs compared to patients not taking NSAIDs. No 
significant difference in IL-1α levels between the groups was observed (P=0.37). (B) IL-1α levels 
of OA patients taking statins compared to patients not taking statins. No significant difference was 
observed between the groups (P=0.32). (C) IL-1α levels of RA patients taking MTX compared to 
patients not taking MTX. A significant difference was observed between the groups (*P=0.026). 
(D) IL-1α levels of PSA patients taking MTX compared to patients not taking MTX. No significant 
difference was observed between the groups (P=0.39).   
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Arthritis Treatment ELISA Number of 
Samples 
Mean (pg/ml) 
OA Non-NSAIDs TNF-α 22 29.74 
OA NSAIDs TNF-α 6 29.00 
OA Non-Statin TNF-α 18 30.80 
OA Statin TNF-α 13 28.00 
RA Non-MTX TNF-α 7 32.60 
RA MTX TNF-α 7 38.34 
PSA Non-MTX TNF-α 3 28.50 
PSA MTX TNF-α 5 49.60 
OA Non-NSAIDs IL-1α 22 155.42 
OA NSAIDs IL-1α 6 85.02 
OA Non-Statin IL-1α 18 118.83 
OA Statin IL-1α 13 172.64 
RA Non-MTX IL-1α 7 412.13 
RA MTX IL-1α 7 120.80 
PSA Non-MTX IL-1α 3 123.10 
PSA MTX IL-1α 5 483.10 
OA Non-NSAIDs IL-1β 22 16.22 
OA NSAIDs IL-1β 6 38.50 
OA No Treatment IL-1β 10 19.31 
OA NSAIDs Only IL-1β 5 45.95 
OA Non-Statin IL-1β 18 26.43 
OA Statin IL-1β 13 9.21 
OA No Treatment IL-1β 10 19.31 
OA Statin Only IL-1β 10 10.25 
RA Non-MTX IL-1β 7 98.10 
RA MTX IL-1β 7 161.03 
PSA Non-MTX IL-1β 3 68.30 
PSA MTX IL-1β 5 62.20 
OA Non-NSAIDs IL-6 22 1244.32 
OA NSAIDs IL-6 6 2445.30 
OA No Treatment IL-6 11 1240.00 
OA NSAIDs Only IL-6 4 1345.00 
OA Non-Statin IL-6 18 1521.64 
OA Statin IL-6 13 1210.20 
RA Non-MTX IL-6 7 4480.00 
RA MTX IL-6 7 3249.10 
PSA Non-MTX IL-6 3 1742.10 
PSA MTX IL-6 5 3305.30 
 
Table 5.2. Number of samples and mean values for the cytokine ELISAs 
Summary of the amount of samples (n) and mean values (pg/ml) for each of the treatment groups 
contained within each arthritis type completed in the human pro-inflammatory cytokine ELISAs.  
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5.5 Levels of ARGSVIL Neoepitope in Synovial Fluid of Arthritic 
Patients 
The C-terminal ARGSVIL neoepitope of aggrecan can be detected following 
cleavage by the aggrecanases ADAMTS4 and ADAMTS5. The levels of 
ARGSVIL were analysed in patient synovial fluid. OA patients undertaking a 
NSAID regimen showed no significant difference in levels of ARGSVIL 
neoepitope compared to patients not undertaking NSAID treatments (Figure 5.9A, 
P=0.76). In contrast, OA patients on an incidental statin regimen showed increased 
ARGSVIL neoepitope levels compared to the non-statin group (Figure 5.9B, 
P=0.05). However, this difference was not significant when other treatment 
regimens were taken into account (P=0.14). There were no significant differences 
in ARGSVIL levels in RA patients prescribed MTX (Figure 5.9C, P=0.42) or in 
PSA patients prescribed MTX (Figure 5.9D, P=0.73) compared to patients not 
prescribed MTX.  
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Figure 5.9. ARGSVIL neoepitope levels in the synovial fluid of patients 
(A) ARGSVIL neoepitope levels (nM) in OA patients taking NSAIDs compared to patients not 
taking NSAIDS. No differences were observed between the groups (P=0.71). (B) ARGSVIL 
neoepitope levels of OA patients taking statins compared to patients not taking statins. A significant 
increase was observed between the groups (°P=0.05; P=0.14 when combination treatment was 
discounted). (C) ARGSVIL neoepitope levels of RA patients taking MTX compared to patients not 
taking MTX. No significant difference was observed between the groups (P=0.42). (D) ARGSVIL 
neoepitope levels of PSA patients taking MTX compared to patients not taking MTX. No significant 
difference was observed between the groups (P=0.73). 
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Arthritis Treatment Number of 
Samples 
Mean ARGSVIL 
(nM) 
OA Non-NSAIDs 21 44.84 
OA NSAIDs 7 47.60 
OA Non-Statin 16 40.70 
OA Statin 13 59.02 
OA No Treatment 9 39.99 
OA Statin Only 11 49.35 
RA Non-MTX 5 60.22 
RA MTX 5 59.60 
PSA Non-MTX 4 33.00 
PSA MTX 5 43.70 
 
Table 5.3. Number of samples and mean values for the aggrecanase ELISA 
Summary of the amount of samples (n) and mean values (nM) for each of the treatment groups 
contained within each arthritis type completed in the aggrecanase ELISA.  
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5.6 DAS28 in RA Patients and Its Correlation with Drug 
Regimens 
DAS28 is a collective index that measures disease activity in 28 joints of RA 
patients and includes swollen and tender joint counts, erythrocyte sedimentation 
rate and a general health score using the visual analogue scale (294). No correlation 
was observed between DAS28 and levels of S-GAG in RA patients (Figure 5.10A, 
P=0.96, R2=≤0.01). The majority of RA patients in this cohort that had up-to-date 
scores were undertaking a MTX regimen (21/23) (Table 5.4), which reflects the 
efficacy of the drug, however, several of those patients continued to have a 
moderate to high DAS28 (11/21 patients presented with scores of 3.2 and above). 
Statins were not found to significantly improve DAS28 in patients (Figure 5.10B, 
P=0.17) nor were NSAIDs (Figure 5.10C, P=0.43). Patients undertaking 
tocilizumab (IL-6 inhibitor) treatments did, however, have significantly lower 
DAS28 (1.37) compared to those not undertaking tocilizumab treatments (Figure 
5.10D, P=0.007). It should be noted that of the patients undertaking tocilizumab, 
2/3 were also taking MTX, and so these effects may not be due to tocilizumab alone 
(Table 5.4).       
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Figure 5.10. DAS28 analysis of RA patients 
(A) No significant correlation between RA patient DAS28 and S-GAG (μg/ml) levels (P=0.96) was 
observed (R2=0.0001). (B) DAS28 of RA patients taking statins compared to those not taking 
statins. No significant difference was observed between the groups (P=0.17). (C) DAS28 of RA 
patients taking NSAIDs compared to those not taking NSAIDs. No significant difference was 
observed between the groups (P=0.85). (D) DAS28 of RA patients taking tocilizumab compared to 
those not taking tocilizumab. A significant difference was observed between the groups (*P=0.007). 
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Patient DAS28 S-GAG (μg/ml) MTX Tocilizumab NSAIDs Statins 
1 0.77 17.58 Yes Yes Yes No 
2 1.66 31.07 No Yes No No 
3 1.67 8.62 Yes Yes No No 
4 2.20 7.24 Yes No No No 
5 2.27 12.96 Yes No No No 
6 2.34 7.95 Yes No No No 
7 2.84 29.08 Yes No No Yes 
8 2.86 12.56 Yes No No No 
9 2.87 13.41 Yes No Yes No 
10 3.11 17.88 Yes No No No 
11 3.21 0 Yes No No Yes 
12 3.78 15.03 Yes No No No 
13 3.92 14.42 Yes No No Yes 
14 4.09 22.44 Yes No No No 
15 4.15 15.75 Yes No No No 
16 4.18 2.96 Yes No No No 
17 4.56 24.98 Yes No No No 
18 4.62 5.18 Yes No Yes Yes 
19 4.87 0 Yes No No No 
20 4.94 18.68 Yes No No No 
21 5.08 25.53 No No No No 
22 5.29 7.64 Yes No No No 
23 5.59 24.72 Yes No No Yes 
 
Table 5.4. DAS28 and S-GAG levels with corresponding treatments in RA patient synovial 
fluid 
DAS28 and corresponding S-GAG (μg/ml) levels from RA patients and predominant treatment 
regimens. Patients taking tocilizumab had significantly decreased DAS28 (P=≤0.01).         
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5.7 Discussion 
The function of the articular joint in arthritis is compromised by the destruction of 
cartilage, which is largely driven by the ADAMTS and MMP proteinases that act 
proteolytically on aggrecan and collagen II, respectively. Pro-inflammatory 
cytokines stimulate the production of these proteases to further exacerbate the 
disease. Current therapeutics such as NSAIDs, biological agents and MTX target 
the immune system and suppress pain and inflammation. However, inhibiting pain 
and inflammation may not necessarily suppress cartilage degradation efficiently. 
Therefore, therapeutics that target both inflammation and cartilage degradation 
concurrently are required for a more rounded approach to the treatment of arthritis. 
The pleiotropic anti-inflammatory and chondroprotective effects of statins in 
arthritis make them an ideal candidate.     
The investigations described in this Chapter demonstrated that an incidental statin 
regimen in OA patients decreased the levels of S-GAG, found in their synovial 
fluid, suggesting statins may protect against articular cartilage destruction in OA. 
Pleiotropic anti-inflammatory and chondroprotective effects have recently become 
evident in RA patients with reductions in inflammatory and disease activity 
markers (201, 202, 295, 296) and in both in vivo and in vitro studies with inhibition 
of MMP production (206, 297) further justifying their use in arthritis treatment, 
especially in co-morbid patients. However, patients with RA and on a statin 
regimen did not have decreased S-GAG in their synovial fluid. Given previous 
studies, it is reasonable to hypothesise that statins may have a greater impact in 
decreasing chronic inflammation, and therefore cartilage destruction, such as that 
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in RA compared to OA. This will require further investigation comparing the 
effects of statins in RA compared to OA. 
In contrast, investigation of ARGSVIL neoepitope levels, indicative of aggrecanase 
activity, revealed that they were increased in OA patients prescribed statins (only 
when used in combination with other treatments) despite overall sulphated GAG 
levels being lower. However, discrepancies in these measurements have been 
reported in a previous study, suggesting there is not a strong positive correlation 
between sulphated GAG levels and ARGSVIL-aggrecan levels, especially given 
some synovial fluid samples with measurable GAG contained no detectable 
ARGSVIL-aggrecan (298). Furthermore, a subset of the OA patient samples used 
for the DMMB assay were used for the detection of ARGSVIL levels, not the entire 
OA cohort, which may also contribute to this discordance. Further comparisons are 
required between these two methods to ascertain their accuracy in the measurement 
of aggrecan degradation with larger numbers of matching samples.  
Previous studies suggest statins may not have significant clinical benefits in RA 
patients (reviewed in (299)). Although trends towards improved C-reactive protein 
(CRP) in RA patients taking rosuvastatin were shown in a double-blinded, placebo-
controlled study, trends towards increased IL-6 levels and no improvement in 
DAS28 scores were also found (205). Moreover, the use of statins has been 
associated with an increased risk of RA in an epidemiological study (300). 
Therefore, the clinical benefits of statins in large-scale, placebo-controlled clinical 
trials in RA and OA are required.  
The Osteoarthritis of the Knee Statin (OAKS) Study (protocol number 521/12, 
NHMRC) is a two-year randomised controlled study conducted through Monash 
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University and the Alfred Hospital in an Australian cohort. This may provide 
further evidence of cartilage protective effects in OA, on contrast to the previous 
studies that focused predominately on RA. The high incidence of co-morbidities 
such as obesity, hypercholesterolemia, cardiovascular disease and arthritis is 
continuing to rise with the ageing population, and therapeutic strategies aimed at 
ameliorating these diseases in combination may provide a more cost-effective 
approach to treatment. 
The use of statins to treat hypercholesterolemia has been criticised recently for 
being prescribed unnecessarily and because patients may suffer from side-effects 
such as muscle pain which often leads to premature discontinuation of their 
treatments. This may lead to concerns about their use in arthritis. However, statins 
are often required given that naturally decreasing cholesterol is increasingly 
difficult in the ageing population. Studies in which adverse events associated with 
the use of statins are reported are often under-reported on or exaggerated and when 
patients are rechallenged they can tolerate statins long-term (301-304). Differences 
in efficacy and side-effects of particular statins as opposed to the entire drug class 
may be responsible for adverse events (301, 302). However, there is a strong need 
to determine the specific nature and incidence of adverse effects of statins before 
they are used as a potential therapeutic in arthritis.        
The association of NSAID use with exacerbated cartilage degradation has been 
indicated by previous studies. Naproxen has been shown to be ineffective at 
blocking aggrecanase activity in bovine articular cartilage (305). Levels of MMP1, 
MMP3 and MMP13, matrix metalloproteinases that promote degradation of 
structural components of the joint including collagen, were increased in synovial 
 131 
 
fluid from a rabbit OA model treated with loxoprofen (306). In vitro studies in 
human articular chondrocytes showed this increase in MMPs with loxoprofen 
treatment was induced by IL-1β and IL-6 (307). Furthermore, diclofenac has been 
shown to induce accelerated radiologic progression of knee and hip OA (308). The 
results in this Chapter indicate that NSAID use in OA patients may promote 
cartilage degradation; therefore, further investigation into the mechanism of action 
of NSAIDs in OA is required. 
MTX, the current gold-standard treatment for RA, elicited no difference in 
sulphated GAGs in synovial fluid and significantly decreased IL-1α levels in RA 
patients analysed in this Chapter. MTX is the primary intervention strategy against 
RA as an immunosuppressive drug modulating adenosine metabolism; however, its 
specific mode of action to reduce radiographic disease progression is unknown. 
Although no effect was seen on the other inflammatory cytokines, ARGSVIL 
neoepitope levels or sulphated GAG levels, the data from this Chapter suggests 
MTX may act locally to reduce pro-inflammatory IL-1α levels in patients. Notably, 
TNF-α is known to induce the production of IL-1 (309), which may represent a 
mechanism downstream of TNF-α by which MTX slows disease progression in 
RA.  
This current investigation also provides some evidence that MTX may not provide 
the same protection in PSA (310), since significantly increased S-GAG was 
observed in PSA patients taking MTX. Although both are autoimmune conditions, 
different mechanisms of action may be responsible for their diverse reactions to the 
same therapy. A randomised placebo-controlled trial of MTX in PSA patients has 
suggested that MTX does not affect several clinical measures of PSA, such as 
swollen joint counts, pain scores, PsARC scores, ACR20 scores and CRP (311). 
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However, it can be noted that PSA patients who require more powerful therapeutics 
may have a worse disease state in the first instance, which may represent a 
confounding factor. Further investigations into the effects of MTX in PSA patients 
are required through clinical trials, as well as mechanistic studies to determine the 
specific mode of action of MTX in both RA and PSA. 
The evidence in this Chapter suggests that statins may decrease propeptide cleavage 
of ADAMTS5 in vitro, potentially supporting the in vivo data in patients that statins 
may decrease cartilage degradation in OA. This retrospective study lacked several 
measures compared to a prospective study. For example, body weight, height, BMI, 
blood to analyse C-reactive protein, and X-rays or MRI scans to determine 
radiographic progression of the disease. However, this study found several 
associations such as lowered S-GAG levels in OA patients on statins, which are 
worthwhile pursuing in large-scale prospective studies to determine whether this 
may be a mechanism by which statins potentially improve the disease state of 
arthritis patients.   
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6 Discussion and Future Directions 
The field of matrix biology has progressed substantially in its five decade history 
with the discovery of the ADAMTS family making a significant contribution. In 
fact, a vast array of developmental and disease processes have been found to be 
regulated by the ADAMTS proteinases and ADAMTSL proteins since their 
discovery in 1997 and 2002, respectively (258, 312). However, the ADAMTS 
family remains less well characterised compared to their MMP counterparts. 
Understanding the core biochemistry of the ADAMTS proteoglycanases is a crucial 
step to determining the mechanisms through which the proteoglycanases function 
in disease and facilitate their pharmacological targeting. This requirement is 
exemplified by the use of synthetic broad-spectrum inhibitors to matrix 
metalloproteinases, which are closely related to the ADAMTS family. In phase II 
clinical trials for cancer patients, these inhibitors actually advanced disease 
progression and caused toxicity due principally to off-target effects caused by tight 
conservation of the metzincin superfamily (313). However, through use of detailed 
biochemical insights, ADAMTS aggrecanase-specific inhibitors in arthritis are 
likely to become a reality in the next few years, which may then pave the way for 
the development of additional targeted ADAMTS pharmacological compounds.       
ADAMTS15 has been largely uncharacterised. However, the research described in 
Chapter 3 has generated a substantial body of knowledge regarding its 
biochemistry. This confirmed ADAMTS15 cleavage of versican occurring at the 
E411A site and that it was activated extracellularly. However, this work also 
unexpectedly revealed that ADAMTS15 was associated with the cell surface unlike 
ADAMTS5. Given this cell surface association, ADAMTS15 may interact with 
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membrane-bound MMPs that could potentially affect its activation. For example, 
ADAMTS4, which also binds to the cell surface, is cleaved by MT4-MMP that 
enables its activation (22). Furthermore, it was established that ADAMTS15 does 
not require its ancillary domain for substrate binding and cleavage of versican 
unlike several proteoglycanases. These biochemical data on the unique properties 
of ADAMTS15 may enable further research into its specific role in colorectal and 
breast cancer, particularly regarding its versicanase activity in these diseases.  
Further investigation into the potential cellular roles of ADAMTS15 - and the 
highly related ADAMTS8 - are also required. Expression of Adamts8 and 
Adamts15 has been identified in the cerebral cortex and interneurons of the 
postnatal mouse brain (314). Therefore, ADAMTS8 and ADAMTS15 may have 
important cooperative roles within the perineuronal net, a specialised extracellular 
matrix containing CSPGs implicated in neuroplasticity (314, 315). Furthermore, 
ADAMTS8 was found to be either downregulated or silenced through methylation 
of its promoter in nasopharyngeal, esophageal, gastric and colorectal human 
carcinoma cell lines, with ADAMTS8 overexpression associated with inhibition of 
migration and enhanced apoptosis of tumour cells (316). Given that ADAMTS15 
is also a tumour suppressor in colorectal cancer (89), ADAMTS8 and ADAMTS15 
may have combinatorial functions in gastrointestinal cancers, despite their 
potentially contrasting roles in breast carcinomas (88). However, the effect of the 
versicanase activity of ADAMTS8 and ADAMTS15 in these contexts has not yet 
been established.  
The ADAMTS proteoglycanases have proven to be crucial regulators of 
developmental morphogenesis, predominantly through their ability to cleave 
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versican. Several developmental processes are affected by their absence, such as 
cardiac valve formation, interdigital web regression, folliculogenesis and 
melanoblast survival, in each case due to a lack of versican processing. 
ADAMTS15 ablation in vivo is required to determine its function during 
development. Adamts15 knockout mice have been generated in-house with 
preliminary analysis suggesting a defect in primary palate formation. Such a 
phenotype that has not previously been uncovered in other ADAMTS 
proteoglycanase knockout mice, although ADAMTS9 has been implicated in 
secondary palate formation (65). Analysis of Adamts15 expression by virtue of a 
LacZ knock-in has revealed broad expression in adults with strong expression in 
the lungs, along with several structures in the brain, such as the thalamus, 
hippocampus and cerebellum, skeletal muscle, testes, fimbriae and fallopian tubes. 
Moreover, expression of Adamts15 in the forebrain and first arch at E11.5 and 
neural crest between E11.5 and E12.5 supports a potential role in craniofacial 
development. In addition, its expression in skeletal muscle from E12.5 onwards is 
also consistent with ADAMTS15 participating in skeletal muscle formation 
cooperatively with ADAMTS5, as previously suggested using cell models (75). 
Therefore, investigation as to whether ADAMTS15 is dysregulated or ablated in 
humans with primary palatal defects such as cleft lip would be worthwhile. 
Furthermore, it would be of interest to determine the role of ADAMTS15 in 
versican processing during development and whether the potential craniofacial 
phenotype is also associated with a lack of versican processing. Importantly, a 
zebrafish adamts15a mutant (orthologue of human ADAMTS15) has been 
generated by the Zebrafish Mutation Project for the Sanger Institute. This model 
will enable additional early developmental analysis of potential defects in the 
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neural crest or mesoderm that are responsible for the formation of the craniofacial 
elements and skeletal muscle. Studying ADAMTS15 in both the zebrafish and 
mouse will provide complementary functional insights.   
The data provided in Chapter 4 implicates ADAMTS5 in zebrafish muscle 
development, consistent with preliminary data in the mouse (75). Further 
characterisation of the musculoskeletal phenotype in Adamts5-/- mice is crucial. 
Assessment of muscle function using a Mouse Muscle Test system to assess 
contractile properties of the muscle (317), as well as coordination and strength tests 
(318) in Adamts5-/- mice would provide important information regarding the 
functional consequences of ADAMTS5 ablation. Furthermore, generation of a 
zebrafish adamts5 mutant using genome editing techniques would allow the 
confirmation of data in Chapter 4 and their extension into adult zebrafish. These 
complementary models will provide a comprehensive understanding of the role of 
ADAMTS5 in musculoskeletal development. 
The interaction between ADAMTS5 and ADAMTS15 in muscle development has 
recently been explored in vitro using skeletal myoblasts (75). These data indicate 
that the generation of combinatorial Adamts5; Adamts15 knockout mouse models 
is worthwhile. This would allow the determination of the interaction of these 
proteoglycanases during mouse muscle development, and the extent of redundancy 
between ADAMTS15 and ADAMTS5 in vivo. Thus, it is probable that these 
combinatorial knockouts will present with an exacerbated musculoskeletal 
phenotype and that ADAMTS15 can compensate for ADAMTS5 and vice-versa. 
Given that an adamts15a zebrafish mutant is available, analysis of an adamts15a; 
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adamts5 mutant could provide additional insights, especially regarding the 
combinatorial effect of adamts15a and adamts5 on the Shh and TGF-β pathways.        
An important area for future research is the study of ADAMTS members 
independent of their catalytic or proteoglycanase activity. In Chapter 4, the ability 
of adamts5 to regulate zebrafish skeletal muscle formation through the TGF-β and 
Shh pathways has revealed a role either wholly or partially independent from its 
catalytic activity. Such a result is not unprecedented. Several ADAMTS proteinases 
have demonstrated roles that are independent of their catalytic activity. For 
example, the anti-angiogenic and anti-tumoural activity of ADAMTS2 is 
independent of its catalytic activity in endothelial cells (319). Furthermore, in a 
mouse melanoma model, overexpression of the inactive E362A mutant or truncated 
C-terminal fragments of ADAMTS4 suppressed melanoma growth and 
angiogenesis as opposed to the active form which enhanced these phenotypes (320). 
In contrast, both active and inactive forms of ADAMTS15 reduced cell migration 
of breast cancer cells (62) and, interestingly, mouse melanoma tumours 
overexpressing ADAMTS5 E411A elicited significantly reduced microvessel 
density, with decreased tumour cell proliferation and increased tumour cell 
apoptosis, similar to the effects of active ADAMTS5 (92). The significance of these 
roles that are independent of their enzymatic functions suggests a reappraisal of 
ADAMTS proteoglycanases, with implications for matrix biology.  
The inhibition of ADAMTS4 and ADAMTS5 remains an important focus in 
rheumatology and matrix biology. Novel therapeutics that may inhibit the 
aggrecanases are of considerable interest. A selective aggrecanase inhibitor is 
currently in clinical trials (235) and two selective ADAMTS5 antibodies have been 
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developed: a recombinant monoclonal antibody directed towards the ancillary 
domain of ADAMTS5 (CRB0017) (236) and a humanised ADAMTS5 monoclonal 
antibody (GSK2394002) (237). The generation of such specific inhibitors towards 
the ADAMTS aggrecanases has provided a strong foundation from which other 
MMP and ADAMTS inhibitors might be generated in the future. However, other 
non-selective inhibitors may also have promise, especially if they are well-tolerated 
in patients with minimal off-target effects. Furthermore, in the case of arthritis, 
treatment cannot be effective unless multiple factors are targeted, which includes 
addressing the chronic inflammation involved in RA and OA. Statins represent one 
possible therapeutic due to their potential to both suppress inflammation and inhibit 
the activity of the aggrecanases. With co-morbidities common, statins may also be 
used to treat several diseases that are especially prevalent in the ageing population, 
such as Alzheimer’s Disease, that has been found to be closely linked to 
cardiovascular disease with statins considered as a treatment to slow or prevent the 
disease (321). Simvastatin was also found to decrease inflammatory markers such 
as IL-6 and C-reactive protein in haemodialysis patients, who have greater risk of 
developing inflammatory conditions (322). In elderly patients suffering from 
benign prostatic hyperplasia and metabolic syndrome, prostate volume and 
International Prostate Symptom Score (IPSS) were decreased upon statin treatment, 
accompanied by decreased total cholesterol and IL-6 levels (323). Furthermore, a 
reduced rate of whole-brain atrophy in secondary progressive multiple sclerosis 
was demonstrated with high-dose simvastatin (324). Combined, these data suggest 
statins may provide protection from a range of disorders that are predominant in 
the elderly, thereby reducing multiple medication use in this vulnerable population.          
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The results of Chapter 5 were inconclusive as to whether statins inhibited 
inflammatory cytokines or aggrecan degradation. Conflicting data were generated, 
showing ARGSVIL levels were higher but S-GAG levels significantly lower in OA 
patients but with no difference in S-GAG levels or DAS28 in RA patients taking 
statins. As a pilot retrospective study, the data obtained was difficult to interpret 
with several conflicting factors involved. Important patient information was 
missing, the patient cohort small and patients were on several different medications 
that may have complicated the study. However, associations were identified 
between statin use and reduced cartilage degradation as measured by decreased S-
GAG in the synovial fluid that can be followed up with large-scale prospective 
studies, such as the OAKS study, which will provide more conclusive evidence as 
to whether statins may inhibit cartilage destruction in OA. 
The conflicting data that has arisen regarding the use of statins in human arthritis 
studies may be attributable to a lack of specificity of the statins towards the 
aggrecanases. Statin use may be associated with similar off-targeting issues that 
occurred in the use of broad-spectrum MMP inhibitors. Therefore, further 
investigation into the specificity is required. For example, given that atorvastatin 
inhibited the cleavage of the ADAMTS5 pro-domain in vitro, it is required to 
determine whether statins also inhibit ADAMTS4. Furthermore, determination of 
the ability of statins to inhibit proteinases not involved in cartilage degradation 
would be important to determine the extent of off-targeting. An in-depth analysis 
of the use of the statins in an OA mouse model would add considerably to the 
human data presented in Chapter 5. This would allow analysis of the integrity of 
the cartilage in the joint itself using DMMB or alcian blue staining, as well as 
determine levels of aggrecanase activity and ARGSVIL or NITEGE neoepitope 
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formation without the complications of additional medications. Furthermore, 
assessment of the extent of inhibition of a broad range of proteinases would also be 
imperative. This model would also allow investigation into statin specificity. For 
example, Adamts5 catalytically-inactive mutant mice are protected from arthritis 
but Adamts4 catalytically-inactive mutant mice are not (71, 78, 79). Treatment of 
both single and combinatorial null (325) or catalytically-inactive Adamts4 and 
Adamts5 mutant mice with statins following the induction of arthritis will identify 
the relative contribution of each aggrecanase to the effect of statins. This will 
provide further scope for human studies to provide a mechanism for its action in 
arthritis.  
The cooperative role of ADAMTS5 and ADAMTS15 in musculoskeletal 
development suggests it is worthwhile to examine this in the context of disease. 
The identification of ADAMTS15 aggrecanase activity (61, 62) and ADAMTS15 
mRNA expression (262) in human cartilage provide scope for the analysis of the 
role of ADAMTS15 in arthritis. Determining the extent of protection upon 
stimulation of arthritis in either the single Adamts15 or combinatorial Adamts15; 
Adamts5 knockout mice will provide a comprehensive understanding of the role of 
ADAMTS15 in arthritis and whether ADAMTS15 cooperates with ADAMTS5 in 
this context. Furthermore, given that Adamts5 has been found to be significantly 
increased in mdx mice (326), the model for Duchenne Muscular Dystrophy (DMD), 
an investigation into the cooperative effect of ADAMTS5 and ADAMTS15 in this 
context would also be worthwhile.  
The environment outside of the cell is an essential mediator of development and 
homeostasis of many types of cells and tissues. Therefore, studying members of the 
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metzincin superfamily in the context of the extracellular matrix is an essential part 
of cell biology research. There are still numerous gaps in our knowledge of the 
structure and function of the ADAMTS family, including the proteoglycanases. 
The biosynthesis, activation, expression pattern and substrate specificity of each 
proteoglycanase is still yet to be defined. Such knowledge is essential to enable 
further understanding of their potential functional roles, and additionally, underpin 
their specific pharmacological targeting in disease. In addition, the initial 
assumption that the proteoglycanases only exert their effects enzymatically via 
proteoglycan processing is most likely incorrect. This is supported by the dynamic 
functions of ADAMTSL proteins and the results described here for ADAMTS5 and 
elsewhere for other family members. Furthermore, analysis of the interactions of 
the ADAMTS proteoglycanases with cell signalling pathways remains in its 
infancy. In this area, the applicability and accessibility of the zebrafish as a model 
will likely come to the fore and become a vital complementary model to the mouse. 
Members of the ADAMTS family have multiple, complex and overlapping roles in 
the extracellular matrix of many different cell types, with further dynamic roles of 
the ADAMTS family in development, homeostasis and disease destined to be 
uncovered in the future.  
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8 Appendix 
Shh 8 hpf Normal  A-P  L-R  
 Mean 
(%) 
SD Mean 
(%) 
SD Mean 
(%) 
SD 
Control 91.90 8.58 5.40 5.58 2.70 1.86 
adamts5-MO 25.53 13.06 37.23 12.50 29.79 1.91 
adamts5-MO + 
ADAMTS5 
56.00 11.24 18.67 9.18 25.33 6.43 
adamts5-MO + 
ADAMTS5 EA 
68.57 5.63 11.43 4.93 18.57 1.71 
Shh 8 hpf Normal  A-P  L-R  
 Mean 
(%) 
SD Mean 
(%) 
SD Mean 
(%) 
SD 
Control 88.52 6.71 9.02 4.81 2.46 3.55 
adamts5-MO 52.50 9.54 21.67 2.30 25.83 9.22 
TGF-β (100 pM) 76.64 2.77 7.48 2.24 15.89 1.98 
adamts5-MO + 
TGF-β (100 pM) 
75.42 7.10 9.32 3.23 15.25 7.53 
Myod 12 hpf Normal Affected     
 Mean 
(%) 
Mean 
(%) 
SD    
Control 80.30 19.70 15.31    
adamts5-MO 50.00 50.00 9.66    
adamts5-MO + 
ADAMTS5 
68.29 31.71 2.44    
adamts5-MO + 
ADAMTS5 EA 
58.51 41.49 6.21    
Myod 12 hpf Normal Affected     
 Mean 
(%) 
Mean 
(%) 
SD    
Control 78.41 21.59 10.48    
adamts5-MO 66.92 33.08 0.79    
Cyclopamine (5 
μM) 
62.37 37.63 22.56    
adamts5-MO + 
Cyclopamine (5 
μM)  
31.90 47.59 9.66    
Myod 12 hpf Normal Affected     
 Mean 
(%) 
Mean 
(%) 
SD    
Control 82.18 17.82 3.05    
adamts5-MO 47.31 52.69 6.76    
Smo agonist (10 
μM) 
41.67 58.33 14.82    
adamts5-MO + 
Smo agonist (10 
μM)  
64.95 35.05 7.18    
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Shh 8 hpf Normal Affected     
 Mean 
(%) 
Mean 
(%) 
SD    
Control 90.63 9.38 1.54    
adamts5 MO 46.03 53.97 11.74    
adamts5 MO + 
p53 MO 
58.06 41.94 1.68    
Myod 12 hpf Normal Affected     
 Mean 
(%) 
Mean 
(%) 
SD    
Control 90.16 9.84 2.23    
adamts5 MO 43.23 53.77 7.57    
adamts5 MO + 
p53 MO 
48.26 51.74 7.13    
 
Appendix Table 1.1. Means and standard deviations for zebrafish adamts5-MO rescue 
experiments 
Means for each group are expressed as percentages (%). Means and standard deviations were 
calculated from n=3 experiments for all except the TGF-β rescue experiments, with means 
calculated from n=4 experiments. Either normal, A-P (anterior-posterior) or L-R (left-right) 
patterning defects were assessed or normal and affected (A-P or L-R patterning defect for shh 
staining or absent paraxial staining for myod staining) embryos were assessed.     
 
 
